Principal Investigator: Elizabeth Thomas
Protocol #18-0487, No Longer Enrolling: 2/27/2020
Locations: Anschutz Health and Wellness; UCD Anschutz Health & Wellness Center; University of Colorado Hospital
More information available at ClinicalTrials.gov: NCT03571048
The purpose of this research is to demonstrate a relationship between cortisol measured in hair, cortisol measured in saliva, and the results of self-reported psychological measures (questionnaires).
Principal Investigator: Julia Byers
Protocol #20-0025, No Longer Enrolling: 1/21/2021
Location: Department Specific Free Standing Clinic;
This study is completed online at your convenience. Participants will complete online surveys (the study takes about 25 minutes to complete).
Principal Investigator: Andrew Novick
Protocol #20-1583, No Longer Enrolling: 10/14/2020
Location: Department Specific Free Standing Clinic;
Protocol #15-1356, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02483988
Principal Investigator: Claire Cofer
Protocol #17-0054, No Longer Enrolling: 3/11/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03012776
Principal Investigator: Claire Cofer
Protocol #17-0371, No Longer Enrolling: 1/8/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03122899
Principal Investigator: Claire Cofer
Protocol #17-1013, No Longer Enrolling: 8/25/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03177473
This is a prospective, multi-center registry of patients treated in accordance with the cleared indications for the Smart, Penumbra Coil 400, and the Penumbra Occlusion Device. Data for each patient are collected in accordance with the standard of care at each participating hospital through one-year follow-up.
Principal Investigator: David Case
Protocol #17-2122, No Longer Enrolling: 7/17/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02729740
The Agili-C™ scaffold is indicated for the treatment of an ICRS grade III or above knee-joint surface lesion(s), with a total treatable area of 1-7cm2 and without severe osteoarthritis (Kellgren-Lawrence grade 0-3)
Principal Investigator: Jeffery Wilson
Protocol #18-2105, No Longer Enrolling: 1/3/2020
Locations: Boulder Sports Clinic; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03299959
Principal Investigator: Marcie Terry
Protocol #18-0073, No Longer Enrolling: 1/15/2020
Location: Childrens Hospital Colorado;
1. To assess the safety and tolerability of QPI-1007 intravitreal (IVT) injections in subjects with recent-onset NAION 2. To determine the effect on visual function of QPI-1007 IVT injections in subjects with recent-onset NAION
Protocol #15-1194, No Longer Enrolling: 11/20/2019
Location: University of Colorado Hospital;
To assess the safety and efficacy of long-term dosing with patisiran in transthyretin-mediated amyloidosis (ATTR) patients with familial amyloidotic polyneuropathy (FAP).
Principal Investigator: Dianna Quan
Protocol #15-1259, No Longer Enrolling: 4/25/2020
Location: University of Colorado Hospital;
To assess the safety, tolerability and efficacy of Accordion Pill carbidopa/levodopa (AP-CD/LD) compared to Immediate Release carbidopa/levodopa (IR CD/LD) in fluctuating PD patients
Protocol #15-2350, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02605434
To evaluate the safety and tolerability of APL-130277 in patients with Parkinson's disease (PD) over a 24 week period
Principal Investigator: Donna Wilber
Protocol #16-0684, No Longer Enrolling: 1/29/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02542696
To compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack in subjects with NMO/NMOSD.
Principal Investigator: Donna Wilber
Protocol #14-0926, No Longer Enrolling: 4/25/2020
Location: University of Colorado Hospital;
To calculate annual SAE rate over time in patients treated with RNS System
Protocol #15-1458, No Longer Enrolling: 11/2/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02403843
To determine whether oral inosine dosed to moderately elevate serum urate (from !U5.7 mg/dL to 7.1-8.0 mg/dL) over 2 years slows clinical decline in early PD.
Protocol #15-2328, No Longer Enrolling: 11/14/2019
Location: University of Colorado Hospital;
To assess the long-term safety of apomorphine continuous infusion in advanced Parkinson?s disease (PD) patients who are unable to achieve adequate motor control despite optimal treatment with noninvasive therapy.
Principal Investigator: Donna Wilber
Protocol #15-1274, No Longer Enrolling: 4/25/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02339064
To demonstrate the efficacy of BAF312 relative to placebo in delaying the time to 3-month confirmed disability progression in patients with SPMS as measured by EDSS.
Principal Investigator: Donna Wilber
Protocol #13-2286, No Longer Enrolling: 4/15/2020
Location: University of Colorado Hospital;
To investigate the efficacy of ocrelizumab compared with placebo in patients with primary progressive multiple sclerosis, as measured by the time to onset of confirmed disability progression over the treatment period, defined as an increase in EDSS that is sustained for at least 12 weeks, based on regularly scheduled visits.
Protocol #11-1327, No Longer Enrolling: 11/12/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01194570
To assess whether the efficacy of ocrelizumab 600 mg (given as dual infusions of 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as a single infusion of 600 mg on Day 1 of each 24-week treatment cycle thereafter) intravenously every 24 weeks is superior to Rebif? as measured by the annualized protocol-defined relapse rate by two years (96 weeks) in patients with relapsing multiple sclerosis.
Protocol #11-1850, No Longer Enrolling: 11/12/2019
Location: University of Colorado Hospital;
To demonstrate the superiority of MD1003, 300 mg/day, over placebo to clinically improve patients with progressive multiple sclerosis (MS).
Principal Investigator: Donna Wilber
Protocol #16-1727, No Longer Enrolling: 4/25/2020
Location: University of Colorado Hospital;
Protocol #17-0089, No Longer Enrolling: 11/6/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03107052
Principal Investigator: Donna Wilber
Protocol #17-0207, No Longer Enrolling: 12/10/2019
Location: University of Colorado Hospital;
Principal Investigator: Donna Wilber
Protocol #17-0679, No Longer Enrolling: 10/9/2020
Location: University of Colorado Hospital;
Protocol #16-0644, No Longer Enrolling: 11/14/2019
Location: University of Colorado Hospital;
Principal Investigator: Donna Wilber
Protocol #16-1354, No Longer Enrolling: 12/12/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02980042
Principal Investigator: Donna Wilber
Protocol #17-1170, No Longer Enrolling: 6/27/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03277248
Protocol #17-1335, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03196375
Protocol #17-1396, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02728752
Principal Investigator: Donna Wilber
Protocol #17-1825, No Longer Enrolling: 2/22/2020
Location: University of Colorado Hospital;
Protocol #17-1854, No Longer Enrolling: 11/19/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02753530
The ARAMIS registry is designed to provide important and timely insight into the management of acute stroke patients who are on novel oral anticoagulant in community practice
Principal Investigator: Gerald McIntosh
Protocol #17-6111, No Longer Enrolling: 2/18/2020
Locations: Medical Center of the Rockies; Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT02478177
Principal Investigator: Donna Wilber
Protocol #17-1816, No Longer Enrolling: 6/20/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02644668
Principal Investigator: Donna Wilber
Protocol #15-0657, No Longer Enrolling: 2/27/2020
Location: University of Colorado Hospital;
Protocol #16-0120, No Longer Enrolling: 11/12/2019
Location: University of Colorado Hospital;
Protocol #17-0087, No Longer Enrolling: 11/6/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02945046
Protocol #17-0088, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
Principal Investigator: Brian Berman
Protocol #18-0113, No Longer Enrolling: 3/12/2020
Locations: Anschutz Health and Wellness; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03407378
Principal Investigator: Elizabeth Chick
Protocol #17-2111, No Longer Enrolling: 4/15/2020
Location: Childrens Hospital Colorado;
Principal Investigator: Donna Wilber
Protocol #15-2388, No Longer Enrolling: 11/13/2020
Location: University of Colorado Hospital;
Principal Investigator: Donna Wilber
Protocol #17-2334, No Longer Enrolling: 10/14/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03309332
Principal Investigator: Donna Wilber
Protocol #18-0375, No Longer Enrolling: 12/20/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03436199
Principal Investigator: Donna Wilber
Protocol #18-0482, No Longer Enrolling: 4/25/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03222973
Protocol #16-2178, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02907177
Protocol #08-0613, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
Protocol #15-2351, No Longer Enrolling: 11/6/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02615873
Principal Investigator: Donna Wilber
Protocol #18-0787, No Longer Enrolling: 11/22/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02927080
Principal Investigator: Donna Wilber
Protocol #16-0121, No Longer Enrolling: 1/6/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02739542
Principal Investigator: Donna Wilber
Protocol #17-0599, No Longer Enrolling: 10/28/2020
Location: University of Colorado Hospital;
Protocol #18-0996, No Longer Enrolling: 11/6/2019
Locations: Brain Imaging Center (BIC); Colorado Research Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03124459
Protocol #18-1262, No Longer Enrolling: 11/6/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03606460
Principal Investigator: Donna Wilber
Protocol #18-0997, No Longer Enrolling: 4/25/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02534844
Protocol #18-1592, No Longer Enrolling: 11/6/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03560739
Protocol #17-2029, No Longer Enrolling: 11/14/2019
Location: University of Colorado Hospital;
Principal Investigator: Donna Wilber
Protocol #18-1875, No Longer Enrolling: 12/4/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03701399
Principal Investigator: Donna Wilber
Protocol #18-2059, No Longer Enrolling: 11/22/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03650114
Principal Investigator: Amanda Piquet
Protocol #18-2152, No Longer Enrolling: 4/25/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03737812
Principal Investigator: Amanda Piquet
Protocol #18-2451, No Longer Enrolling: 4/25/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03737851
Principal Investigator: Dianna Quan
Protocol #18-2341, No Longer Enrolling: 4/25/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03772587
Principal Investigator: Donna Wilber
Protocol #18-2423, No Longer Enrolling: 2/29/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03710707
Principal Investigator: Dianna Quan
Protocol #18-2237, No Longer Enrolling: 11/22/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03759379
Protocol #18-2536, No Longer Enrolling: 11/6/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03669588
Principal Investigator: Donna Wilber
Protocol #18-2535, No Longer Enrolling: 11/22/2019
Locations: Brain Imaging Center (BIC); Colorado Research Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03689972
Principal Investigator: Donna Wilber
Protocol #19-0363, No Longer Enrolling: 4/25/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03567057
Principal Investigator: Donna Wilber
Protocol #19-0025, No Longer Enrolling: 2/21/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03781167
Principal Investigator: Donna Wilber
Protocol #19-0478, No Longer Enrolling: 7/7/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03922711
Protocol #19-0720, No Longer Enrolling: 11/14/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03943290
Principal Investigator: Danielle McDermott
Protocol #19-1396, No Longer Enrolling: 2/7/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03478982
Principal Investigator: Donna Wilber
Protocol #19-1599, No Longer Enrolling: 3/28/2020
Locations: Brain Imaging Center (BIC); University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04001517
Principal Investigator: Donna Wilber
Protocol #19-1505, No Longer Enrolling: 3/28/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04152083
This is a clinical trial of radiation that will be administered after a lumpectomy, to the breast and lymph nodes or mastectomy, to the area where the breast used to be and lymph nodes. This is done to see if giving radiation as described above will help women live longer.
Principal Investigator: Chelsea Schaefer
Protocol #13-2454, No Longer Enrolling: 12/31/2020
Locations: Greeley Campus; Harmony Campus; Lone Tree Medical Center; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01872975
Principal Investigator: CINDY O'BRYANT
Protocol #14-1764, No Longer Enrolling: 1/29/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02372539
This is a clinical trial of standard of care and SBRT that will be administered by radiotherapy and is investigational.
Protocol #15-0136, No Longer Enrolling: 10/1/2019
Locations: Greeley Hospital; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02364557
Principal Investigator: Daniel Bowles
Protocol #15-0801, No Longer Enrolling: 9/4/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02091141
Principal Investigator: Tim Garrington
Protocol #15-1618, No Longer Enrolling: 5/22/2020
;
More information available at ClinicalTrials.gov: NCT02306161
Principal Investigator: Chelsea Mason
Protocol #15-1574, No Longer Enrolling: 1/8/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02568267
Principal Investigator: Jennifer Diamond
Protocol #15-1135, No Longer Enrolling: 3/19/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02719691
Principal Investigator: Daniel Bowles
Protocol #15-1932, No Longer Enrolling: 2/26/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02393690
Principal Investigator: Victor Villalobos
Protocol #15-1995, No Longer Enrolling: 11/27/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02659020
Protocol #15-2301, No Longer Enrolling: 11/8/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02628067
1. To determine the safety profile of orally administered AP32788 2. To identify the RP2D, dose-limiting toxicities (DLTs), and the maximum tolerated dose (MTD) of AP32788 3 .To determine the pharmacokinetic (PK) profile of AP32788 and its active metabolites, AP32960 and AP32914 4. To evaluate the anti-tumor activity of AP32788 in NSCLC patients with EGFR or HER2 mutations 5. To explore associations between tumor and plasma biomarkers and AP32788 efficacy and safety
Principal Investigator: Molly Throdahl
Protocol #16-0208, No Longer Enrolling: 2/14/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02716116
Principal Investigator: CHALAUNDA SCOTT
Protocol #16-0207, No Longer Enrolling: 7/31/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02671435
Principal Investigator: Nicole Conti
Protocol #16-0506, No Longer Enrolling: 9/30/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02706626
Principal Investigator: Jennifer Diamond
Protocol #16-0628, No Longer Enrolling: 7/10/2020
Locations: Lone Tree Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02702492
Principal Investigator: Jenna Buehler
Protocol #16-0708, No Longer Enrolling: 10/6/2020
Locations: Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02502266
Principal Investigator: Andrea Glass
Protocol #16-1057, No Longer Enrolling: 7/15/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01827384
Protocol #16-1225, No Longer Enrolling: 11/12/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03030287
Protocol #16-1241, No Longer Enrolling: 10/4/2019
Locations: Greeley Hospital; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02595944
Principal Investigator: Carmen Rivera
Protocol #16-1205, No Longer Enrolling: 12/17/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02285439
To establish safety and efficacy of Niraparib in patients with targeted DNA- repair anomalies
Principal Investigator: Michael Wacker
Protocol #16-1470, No Longer Enrolling: 4/9/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02854436
A rollover study to continue to document patients previously enrolled to an enzalutamide study
Principal Investigator: Elaine Lam
Protocol #16-1640, No Longer Enrolling: 5/28/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02960022
Principal Investigator: Carmen Rivera
Protocol #16-1825, No Longer Enrolling: 8/7/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02644460
A comparison of Gem/Cis +/- VX-970
Principal Investigator: Mary Anduha
Protocol #16-1951, No Longer Enrolling: 12/31/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02567409
Atezolizumab vs. placebo as adjuvant therapy post nephrectomy
Protocol #16-1420, No Longer Enrolling: 10/28/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03024996
Principal Investigator: Anna Franklin
Protocol #16-2269, No Longer Enrolling: 2/9/2021
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02979522
Principal Investigator: ANDREA MARTINSEN
Protocol #16-2025, No Longer Enrolling: 9/23/2020
Locations: Lone Tree Medical Center; University of California San Francisco; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03088930
Principal Investigator: Daniel Bowles
Protocol #16-2230, No Longer Enrolling: 3/31/2020
Locations: Dana Farber Cancer Institute; MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; The Ohio State University Comprehensive Cancer Center; UCLA, Jonsson Cancer Center; University of Colorado Hospital; University of Michigan Comprehensive Cancer Center;
More information available at ClinicalTrials.gov: NCT02973997
To assess the efficacy of Prmbrolizumab plus Cabozantinib in patients with metastatic renal cell carcinoma
Principal Investigator: Anne Martin
Protocol #16-2300, No Longer Enrolling: 12/19/2020
Locations: Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Lone Tree Medical Center; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03149822
Principal Investigator: Sheri Neu
Protocol #16-2248, No Longer Enrolling: 2/24/2021
Locations: Lone Tree Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03013218
Protocol #17-0029, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03119467
Principal Investigator: Karl Lewis
Protocol #16-2696, No Longer Enrolling: 12/24/2020
Locations: Lone Tree Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03132636
Principal Investigator: Stephen Leong
Protocol #16-2407, No Longer Enrolling: 4/11/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03069469
Principal Investigator: Sarah Davis
Protocol #17-0280, No Longer Enrolling: 10/23/2020
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02834013
Principal Investigator: Derek Schatz
Protocol #17-7836, No Longer Enrolling: 12/17/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02516696
A comparison of Nivolumab vs no Nivolumab prior to nephrectomy.
Principal Investigator: Geetika Srivastava
Protocol #17-0406, No Longer Enrolling: 11/25/2020
Locations: Greeley Campus; Harmony Campus; Lone Tree Medical Center; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03055013
Principal Investigator: Carolyn Dilz
Protocol #17-0491, No Longer Enrolling: 2/7/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02983045
Principal Investigator: Rachel Telles
Protocol #17-0614, No Longer Enrolling: 1/3/2020
Locations: Greeley Hospital; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02893930
Protocol #17-0173, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03135262
Principal Investigator: Caralyn Henderson
Protocol #17-0828, No Longer Enrolling: 5/14/2020
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT03137771
Protocol #17-0767, No Longer Enrolling: 10/25/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02817633
Principal Investigator: Karl Lewis
Protocol #17-0996, No Longer Enrolling: 12/29/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03070392
A comparison of Nivolumab + cabozantinib vs Nivolumab + Ipilimumab + Cabozantinib vs Sunitinb in patients with kidney cancer
Protocol #17-1121, No Longer Enrolling: 10/17/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03141177
Principal Investigator: Dan Pollyea
Protocol #17-0754, No Longer Enrolling: 1/16/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03318016
Principal Investigator: Matthew Lee
Protocol #17-1167, No Longer Enrolling: 2/8/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03184870
Principal Investigator: Carmen Rivera
Protocol #17-1045, No Longer Enrolling: 10/27/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02867592
Principal Investigator: Dan Pollyea
Protocol #17-7821, No Longer Enrolling: 2/6/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03466294
Principal Investigator: Derek Schatz
Protocol #17-0900, No Longer Enrolling: 3/28/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03218683
Principal Investigator: Christine Fisher
Protocol #17-1333, No Longer Enrolling: 10/8/2020
Locations: Lone Tree Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03325634
Protocol #17-0694, No Longer Enrolling: 11/14/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03253575
Principal Investigator: Ana Nguyen
Protocol #17-1452, No Longer Enrolling: 12/14/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02675439
Protocol #17-1501, No Longer Enrolling: 10/28/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02574455
Principal Investigator: Karl Lewis
Protocol #17-1474, No Longer Enrolling: 2/9/2021
Locations: Lone Tree Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02360579
Principal Investigator: Chris Lieu
Protocol #17-1021, No Longer Enrolling: 9/16/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03374254
Principal Investigator: Carmen Rivera
Protocol #17-1790, No Longer Enrolling: 1/8/2021
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT01089101
Principal Investigator: Anna Franklin
Protocol #17-1777, No Longer Enrolling: 7/10/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03263936
Assessment of TAK 228 in metastatic kidney cancer
Principal Investigator: Elaine Lam
Protocol #17-0727, No Longer Enrolling: 2/12/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03097328
Principal Investigator: Joanne Hilden
Protocol #17-0619, No Longer Enrolling: 6/24/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02828358
Principal Investigator: Sarah Tarver
Protocol #17-1834, No Longer Enrolling: 8/13/2020
Locations: Greeley Campus; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT03033576
Principal Investigator: ANDREA MARTINSEN
Protocol #17-1757, No Longer Enrolling: 6/6/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03381274
Principal Investigator: Ana Nguyen
Protocol #17-1943, No Longer Enrolling: 7/10/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03359850
Principal Investigator: Aislinn Lederman
Protocol #17-1974, No Longer Enrolling: 12/11/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03393000
Principal Investigator: Anna Franklin
Protocol #17-1481, No Longer Enrolling: 8/15/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02703272
Principal Investigator: Brandon McMahon
Protocol #17-2086, No Longer Enrolling: 2/26/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03144687
Principal Investigator: Sarah Davis
Protocol #17-1940, No Longer Enrolling: 12/6/2019
Locations: Rocky Mountain Regional VA Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03409016
Principal Investigator: Carmen Rivera
Protocol #17-1845, No Longer Enrolling: 8/27/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03451825
Principal Investigator: AMANDA KUPNIEWSKI
Protocol #17-2198, No Longer Enrolling: 7/21/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03345784
Principal Investigator: Rachel Telles
Protocol #17-2189, No Longer Enrolling: 3/28/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03336216
Principal Investigator: Carmen Rivera
Protocol #17-2257, No Longer Enrolling: 11/18/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT01964300
Principal Investigator: Chelsea Mason
Protocol #17-2450, No Longer Enrolling: 8/21/2020
Locations: Lone Tree Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03425279
Principal Investigator: Ana Nguyen
Protocol #17-2381, No Longer Enrolling: 10/9/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02496663
Principal Investigator: Alexis Leal
Protocol #17-2226, No Longer Enrolling: 3/19/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03449030
Principal Investigator: Erin Schenk
Protocol #17-2451, No Longer Enrolling: 9/4/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02988817
Principal Investigator: Andrew Coy
Protocol #18-0033, No Longer Enrolling: 9/11/2020
Locations: Lone Tree Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03369223
Principal Investigator: Gwendolyn Wade
Protocol #17-2208, No Longer Enrolling: 2/17/2021
Locations: Lone Tree Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03332797
Principal Investigator: Carmen Rivera
Protocol #18-0320, No Longer Enrolling: 6/5/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03320330
Principal Investigator: Anne Martin
Protocol #17-0466, No Longer Enrolling: 9/29/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03475004
Principal Investigator: AMANDA KUPNIEWSKI
Protocol #18-0154, No Longer Enrolling: 4/25/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03459222
Principal Investigator: Karl Lewis
Protocol #18-0247, No Longer Enrolling: 3/25/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03864042
Protocol #17-6238, No Longer Enrolling: 10/1/2019
Locations: Greeley Hospital; Harmony Campus; Medical Center of the Rockies; Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT02793583
Principal Investigator: ROBYN SWING
Protocol #18-0286, No Longer Enrolling: 8/13/2020
Locations: Greeley Campus; Harmony Campus; Lone Tree Medical Center; Long's Peak Hospital; Longs Peak Hospital; Medical Center of the Rockies; Memorial Hospital Central; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03258554
Principal Investigator: ROBYN SWING
Protocol #18-0504, No Longer Enrolling: 5/13/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03148327
Principal Investigator: Caitlin Hutchinson
Protocol #18-0167, No Longer Enrolling: 12/23/2020
Location: Rocky Mountain Regional VA Medical Center;
Principal Investigator: ROBYN SWING
Protocol #18-0285, No Longer Enrolling: 10/7/2020
Locations: Lone Tree Medical Center; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03367702
Protocol #18-0269, No Longer Enrolling: 11/8/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03465722
Principal Investigator: Jillian Welker
Protocol #18-0541, No Longer Enrolling: 4/2/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03509012
A comparison of Neoadjuvant Nivolumab with versus without Urelumab in patients with cisplatin-ineligible bladder cancer
Principal Investigator: Elizabeth Kessler
Protocol #18-0760, No Longer Enrolling: 6/2/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02845323
A comparison of Talazoparib plus enzalutamide vs placebo plus enzalutamide
Principal Investigator: Elizabeth Kessler
Protocol #18-0884, No Longer Enrolling: 4/9/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03395197
Protocol #18-0871, No Longer Enrolling: 10/23/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03611556
Principal Investigator: Sheri Neu
Protocol #18-0965, No Longer Enrolling: 4/10/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03637491
A comparison of enzalutamide with and without CPI1205 in patients with metastatic prostate cancer
Principal Investigator: Daniel Heck
Protocol #18-0990, No Longer Enrolling: 3/7/2020
Locations: Lone Tree Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03480646
Principal Investigator: Sana Karam
Protocol #18-0606, No Longer Enrolling: 3/3/2021
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Pikes Peak Regional Hospital; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03635164
Principal Investigator: Robert Hoyer
Protocol #18-6506, No Longer Enrolling: 12/5/2019
Locations: Memorial Hospital Central; Memorial Hospital North; Pikes Peak Regional Hospital;
More information available at ClinicalTrials.gov: NCT03382912
Principal Investigator: Antonio Jimeno
Protocol #18-1049, No Longer Enrolling: 12/22/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03083873
Principal Investigator: Dan Pollyea
Protocol #18-1093, No Longer Enrolling: 8/26/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03466320
Principal Investigator: Brad Haverkos
Protocol #18-0708, No Longer Enrolling: 12/18/2020
Locations: City of Hope Cancer Center; Lone Tree Medical Center; Thomas Jefferson University Hospital Cancer Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03586999
Principal Investigator: Elissa Kolva
Protocol #18-1100, No Longer Enrolling: 11/10/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03662698
Principal Investigator: Alicia Deschaine
Protocol #18-1203, No Longer Enrolling: 7/28/2020
Locations: Memorial Hospital Central; Memorial Hospital North;
More information available at ClinicalTrials.gov: NCT03087708
Principal Investigator: Sheri Neu
Protocol #18-1263, No Longer Enrolling: 2/5/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03744468
Protocol #18-1430, No Longer Enrolling: 10/23/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03662659
Principal Investigator: Alexis Leal
Protocol #18-1431, No Longer Enrolling: 4/16/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03658772
Principal Investigator: ROBYN SWING
Protocol #18-1477, No Longer Enrolling: 3/4/2020
Locations: Greeley Hospital; Harmony Campus; Longs Peak Hospital; Medical Center of the Rockies; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03217266
Protocol #18-1214, No Longer Enrolling: 10/2/2019
Locations: Greeley Hospital; Harmony Campus; Medical Center of the Rockies; Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT03499808
Principal Investigator: Kian Behbakht
Protocol #18-1337, No Longer Enrolling: 2/19/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03522246
Principal Investigator: Ana Nguyen
Protocol #18-1659, No Longer Enrolling: 6/2/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02729298
Evaluating the addition of apalutamide to radiotherapy for men with recurrent prostate cancer
Principal Investigator: Sherryl Esplana
Protocol #18-1742, No Longer Enrolling: 2/14/2020
Locations: Greeley Hospital; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Pikes Peak Regional Hospital; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03371719
Principal Investigator: Karl Lewis
Protocol #18-1422, No Longer Enrolling: 12/18/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03597282
Principal Investigator: Antonio Jimeno
Protocol #18-1721, No Longer Enrolling: 1/27/2021
Locations: Greeley Campus; Highlands Ranch Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03616574
Protocol #18-1741, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03666988
Protocol #18-1595, No Longer Enrolling: 11/19/2019
Locations: Memorial Hospital Central; Memorial Hospital North;
More information available at ClinicalTrials.gov: NCT02856581
Protocol #18-1869, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03770689
Principal Investigator: Derek Schatz
Protocol #18-1983, No Longer Enrolling: 3/21/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03651128
Principal Investigator: Anosheh Afghahi
Protocol #18-1933, No Longer Enrolling: 11/25/2020
Locations: Lone Tree Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03330847
A comparison of Provenge versus active surveillance in low risk prostate cancer patients.
Protocol #18-1980, No Longer Enrolling: 10/5/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03686683
Principal Investigator: Flora Martinez
Protocol #18-1858, No Longer Enrolling: 7/10/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03785964
Principal Investigator: Anthony Elias
Protocol #18-1856, No Longer Enrolling: 12/1/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03673501
Principal Investigator: Daniel Bowles
Protocol #18-1919, No Longer Enrolling: 1/8/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03690388
Principal Investigator: Kathleen Dorris
Protocol #18-2309, No Longer Enrolling: 9/30/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02502708
Principal Investigator: Angie Valdez
Protocol #18-6118, No Longer Enrolling: 11/26/2019
Locations: Memorial Hospital Central; Memorial Hospital North; Pikes Peak Regional Hospital;
More information available at ClinicalTrials.gov: NCT03685344
Principal Investigator: Chris Lieu
Protocol #18-2293, No Longer Enrolling: 1/31/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03693170
Principal Investigator: Denise M. Damek
Protocol #18-2219, No Longer Enrolling: 8/28/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03684811
Principal Investigator: Anthony Elias
Protocol #18-2334, No Longer Enrolling: 7/11/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03253679
A comparison of M6620 + Carboplatin versus Docetaxel + Carboplatin in metastatic castrate-resistant prostate cancer
Principal Investigator: Elizabeth Kessler
Protocol #18-2398, No Longer Enrolling: 8/7/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03517969
Principal Investigator: ANDREA MARTINSEN
Protocol #18-2488, No Longer Enrolling: 12/16/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03505710
Principal Investigator: Bradley Corr
Protocol #18-2466, No Longer Enrolling: 4/10/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03797326
Principal Investigator: Nicole Conti
Protocol #18-2487, No Longer Enrolling: 7/1/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03822351
Principal Investigator: David Raben
Protocol #16-2621, No Longer Enrolling: 1/6/2021
Locations: Denver Health Medical Center; National Jewish Health; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03016403
Protocol #18-0710, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03802747
Principal Investigator: Elena Shagisultanova
Protocol #18-2357, No Longer Enrolling: 4/9/2020
Locations: Lone Tree Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03701334
Principal Investigator: Gianna Morales
Protocol #19-0011, No Longer Enrolling: 1/30/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03805841
Principal Investigator: CINDY O'BRYANT
Protocol #19-0233, No Longer Enrolling: 4/10/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03726333
Principal Investigator: Jennifer Diamond
Protocol #19-0326, No Longer Enrolling: 3/25/2020
Locations: Highlands Ranch Hospital; Lone Tree Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03901339
Principal Investigator: Danielle Gilbert
Protocol #19-0161, No Longer Enrolling: 4/3/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03911869
Principal Investigator: Diana Medgyesy
Protocol #19-6041, No Longer Enrolling: 9/9/2020
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT03778931
Principal Investigator: Nicole Conti
Protocol #19-0702, No Longer Enrolling: 12/21/2019
Location: University of Colorado Hospital;
Comparison of drink supplements in evaluation of post-operative Bladder cancer patients
Protocol #19-0818, No Longer Enrolling: 10/8/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03757949
Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate cancer
Protocol #19-0819, No Longer Enrolling: 10/17/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03697148
Principal Investigator: Anna Sweetser
Protocol #19-1151, No Longer Enrolling: 6/12/2020
Locations: Lone Tree Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03738228
Principal Investigator: Jillian Murphy
Protocol #19-1121, No Longer Enrolling: 10/27/2020
Locations: Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Medical Center of the Rockies; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03793179
Principal Investigator: Gianna Morales
Protocol #19-1317, No Longer Enrolling: 7/21/2020
Locations: Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Lone Tree Medical Center; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03845296
Principal Investigator: Gianna Morales
Protocol #19-1318, No Longer Enrolling: 11/21/2020
Locations: Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Lone Tree Medical Center; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03971474
Principal Investigator: Jenna Sopfe
Protocol #19-1111, No Longer Enrolling: 12/4/2020
Locations: Childrens Hospital Colorado; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04066218
Principal Investigator: Elaine Lam
Protocol #19-1394, No Longer Enrolling: 3/17/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03237780
Principal Investigator: AMANDA CHILDS
Protocol #X19-9999, No Longer Enrolling: 6/2/2020
Locations: Department Specific Free Standing Clinic; Highlands Ranch Hospital; University of Colorado Hospital;
Principal Investigator: Bradley Corr
Protocol #19-0591, No Longer Enrolling: 7/28/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03776812
Principal Investigator: Leah Adams
Protocol #19-0327, No Longer Enrolling: 9/26/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03778931
Principal Investigator: Cathy Bradley
Protocol #18-0156, No Longer Enrolling: 11/28/2019
;
Principal Investigator: Bradley Corr
Protocol #19-2018, No Longer Enrolling: 2/22/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03880019
The participant will be treated with microneedle arrays containing doxorubicin (D-MNA) or microneedle arrays containing placebo. The D-MNA or MNA-placebo is applied to the BCC lesion and secured to the skin with a self-adhesive bandage. The D-MNA is removed from the skin after 30 minutes. Each participant will receive three (3) weekly applications of the D-MNA unless a dose limiting toxicity (DLT) requires skipping or postponement of an application. The investigational product is chemotherapeutic agent doxorubicin (25 ug, 50 ug, 100 ug, or 200 ug) delivered to specific skin strata by a novel delivery system, MNA or placebo delivered to specific skin strata by MNA.
Principal Investigator: Cheryl Armstrong
Protocol #19-0035, No Longer Enrolling: 12/18/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03646188
Principal Investigator: Emily Drees
Protocol #19-0946, No Longer Enrolling: 3/21/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03964727
Principal Investigator: Meredith Waring
Protocol #19-0820, No Longer Enrolling: 1/6/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03383458
Principal Investigator: Caralyn Henderson
Protocol #15-6056, No Longer Enrolling: 12/25/2019
Location: Memorial Hospital Central;
Principal Investigator: Jose Pacheco
Protocol #19-2129, No Longer Enrolling: 1/29/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03896503
Principal Investigator: Brandon McMahon
Protocol #19-0562, No Longer Enrolling: 1/22/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03755518
Principal Investigator: Dan Pollyea
Protocol #18-0818, No Longer Enrolling: 3/21/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03502668
Principal Investigator: Heather Leach
Protocol #19-0323, No Longer Enrolling: 10/13/2020
Locations: Anschutz Health and Wellness; UCD Anschutz Health & Wellness Center;
More information available at ClinicalTrials.gov: NCT03976193
Principal Investigator: Joshua Saginaw
Protocol #19-1346, No Longer Enrolling: 12/21/2019
Location: University of Colorado Hospital;
Principal Investigator: Kayla Pacheco
Protocol #19-0536, No Longer Enrolling: 9/30/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03565900
Principal Investigator: Alicia Deschaine
Protocol #19-6066, No Longer Enrolling: 7/25/2020
Locations: Memorial Hospital Central; Memorial Hospital North; Pikes Peak Regional Hospital;
More information available at ClinicalTrials.gov: NCT03840902
Principal Investigator: Angie Valdez
Protocol #19-2828, No Longer Enrolling: 4/8/2020
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT03914612
Principal Investigator: Kathleen Dorris
Protocol #18-2000, No Longer Enrolling: 12/2/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT01503086
Principal Investigator: KELLY MALONEY
Protocol #18-0198, No Longer Enrolling: 12/22/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02900976
Principal Investigator: Karl Lewis
Protocol #19-1297, No Longer Enrolling: 11/14/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03132675
Principal Investigator: Brad Haverkos
Protocol #19-1431, No Longer Enrolling: 8/20/2020
Locations: Lone Tree Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03770000
Principal Investigator: Elaine Lam
Protocol #19-2560, No Longer Enrolling: 9/4/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04262336
Principal Investigator: Derek Schatz
Protocol #19-2724, No Longer Enrolling: 3/24/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03907488
Principal Investigator: Sana Karam
Protocol #19-2326, No Longer Enrolling: 12/4/2020
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03952585
Principal Investigator: Emily Palmeri
Protocol #19-3023, No Longer Enrolling: 1/7/2021
Locations: Childrens Hospital Colorado; University of Colorado Hospital;
Principal Investigator: Gianna Morales
Protocol #19-2390, No Longer Enrolling: 2/4/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03974022
Principal Investigator: Antonio Jimeno
Protocol #17-1756, No Longer Enrolling: 2/12/2021
Locations: Highlands Ranch Hospital; Lone Tree Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03765918
Principal Investigator: Joshua Saginaw
Protocol #19-1759, No Longer Enrolling: 8/12/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04077099
Principal Investigator: Gianna Morales
Protocol #20-0564, No Longer Enrolling: 11/21/2020
Locations: Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Lone Tree Medical Center; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04173507
Principal Investigator: Danielle Gilbert
Protocol #19-1711, No Longer Enrolling: 1/20/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03897036
Principal Investigator: AMY KEATING
Protocol #18-1990, No Longer Enrolling: 10/3/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03497273
Principal Investigator: Derek Schatz
Protocol #19-1195, No Longer Enrolling: 1/30/2021
Locations: Lone Tree Medical Center; University of Colorado Hospital; University of Michigan;
More information available at ClinicalTrials.gov: NCT04535102
To assess whether, in participants with pre-diabetes, oral daily vitamin D3 (cholecalciferol) supplementation reduces the rate of progression from prediabetes to diabetes.
Protocol #14-2402, No Longer Enrolling: 11/14/2019
Locations: CTRC-adult; University of Colorado Hospital;
This study is a clinical research study consisting of 2 different periods (in the Core phase) with a total expected duration of 48 weeks and the first 12 weeks being a double-blind placebo controlled portion and then 36 weeks of study drug treament, followed by an optional extension phase for an additional 52 weeks (in which case the total duration of study participation will be up to 100 weeks). It is sponsored by the pharmaceutical company named Novartis (the ?Sponsor?). Around 69 patients will join this study in approximately 35 centers located in different countries (around 12) across the world. The purpose of this study is to confirm the effectiveness and safety of osilodrostat in treating patients with Cushing's Disease.
Principal Investigator: Janice Kerr
Protocol #17-0483, No Longer Enrolling: 3/10/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02697734
Principal Investigator: Ashley Pratt-Cordova
Protocol #17-0399, No Longer Enrolling: 2/10/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03252353
Principal Investigator: Emma Hulseberg-Dwyer
Protocol #17-0366, No Longer Enrolling: 7/22/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03373435
Principal Investigator: Chantal Underkofler
Protocol #17-2118, No Longer Enrolling: 1/6/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03452228
Principal Investigator: Benjamin Echalier
Protocol #18-0756, No Longer Enrolling: 2/10/2021
Location: University of Colorado Hospital;
Principal Investigator: Sharolene Goodman
Protocol #18-2230, No Longer Enrolling: 10/26/2020
Location: Childrens Hospital Colorado;
Protocol #18-1934, No Longer Enrolling: 10/8/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03770637
Principal Investigator: Chantal Underkofler
Protocol #18-2435, No Longer Enrolling: 10/6/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03285308
Principal Investigator: Marcie Terry
Protocol #17-1543, No Longer Enrolling: 8/29/2020
Location: Childrens Hospital Colorado;
Principal Investigator: Kathleen Peoples
Protocol #18-2130, No Longer Enrolling: 12/21/2020
Location: Childrens Hospital Colorado;
Principal Investigator: Marcie Terry
Protocol #18-1716, No Longer Enrolling: 12/7/2020
Location: Childrens Hospital Colorado;
DUR-928 (investigational drug)
Principal Investigator: Lisa Forman
Protocol #18-0123, No Longer Enrolling: 1/6/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03394781
The safety of medications to treat UC and CD during pregnancy and lactation is of significant interest of childbearing potential, as these medications may be transferred in utero or though breast milk form nursing mothers to their newborns. It is unknown whether vedolizumab is present in human breast milk.
Principal Investigator: Blair Fennimore
Protocol #16-0066, No Longer Enrolling: 6/9/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02559713
Principal Investigator: John Norvell
Protocol #18-1144, No Longer Enrolling: 1/6/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03554759
Participants will come into the clinic for 5 visits which will last 1.5-3.5 hours long. Each visit has an Audiologist and an Otologist component in it. Each participant will need to complete daily diary entries by calling into phone number and answering some questions.
Principal Investigator: Kristi Engle Folchert
Protocol #18-1269, No Longer Enrolling: 3/2/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03664674
Principal Investigator: Laura Temple
Protocol #18-1057, No Longer Enrolling: 12/3/2019
Location: University of Colorado Hospital;
Principal Investigator: Laura Temple
Protocol #19-2598, No Longer Enrolling: 7/23/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04237207
A new study is looking at a device that would strengthen the muscles of the mouth to make eating and drinking easier for those who have trouble swallowing. Participants will be randomized to either the group using the investigational device for tongue exercise or the group using standard of care tongue depressors. All participants will receive compensation for participating. To develop a low-cost device that improves patient outcomes by eliciting the same methods of action of existing higher cost devices. To assess if exercising the tongue with this novel device can achieve increased tongue strength among individuals with Parkinson's disease.
Principal Investigator: Laura Temple
Protocol #19-1850, No Longer Enrolling: 11/18/2020
Location: University of Colorado Hospital;
Principal Investigator: Emily Mccourt
Protocol #16-0145, No Longer Enrolling: 2/10/2021
Location: Childrens Hospital Colorado;
Principal Investigator: Derek Schatz
Protocol #19-2807, No Longer Enrolling: 6/6/2020
Locations: Lone Tree Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04240808
This study plans to learn more about the relationship between fertility and obesity.
Principal Investigator: Alex Polotsky
Protocol #15-0474, No Longer Enrolling: 3/2/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02478775
The goal of this study is to vary the amount of F-TAF dosing and see if the drug levels in dried blood spots (DBS) change in a predictable way.
Protocol #16-0972, No Longer Enrolling: 10/16/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02962739
We are looking for healthy men to participate in a research study on the effects of sleep restriction on bone. The purpose of this research is to understand how shortened sleep affects bone metabolism. The study includes an intervention phase consisting of a 1-week outpatient and 8-night inpatient stay. Participants will be observed after discharge from the intervention phase for 3 weeks. Principal Investigator, Christine Swanson, MD, MCR (COMIRB #18-0015)
Principal Investigator: Christine Swanson
Protocol #18-0015, No Longer Enrolling: 10/8/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03733483
Principal Investigator: Ilona Schwarz
Protocol #19-0802, No Longer Enrolling: 2/21/2020
Locations: Barbara Davis Center; UCD Barbara Davis Center;
What you receive for participating: -Personalized information about your energy expenditure ("metabolism") -Five total days of food -Monetary compensationTest whether accelerometer-based measures of physical activity from Actigraph and ActivPAL accelerometers can be used to improve the calculation of TEF in whole room calorimeter studies.
Principal Investigator: Sarah Purcell
Protocol #20-0191, No Longer Enrolling: 12/11/2020
Location: University of Colorado Hospital;
Principal Investigator: Alison Saville
Protocol #19-3006, No Longer Enrolling: 2/4/2021
Locations: CHOC ? Children?s Hospital of Orange County; UCLA - University of California; UCLA, Jonsson Cancer Center; University of Colorado Hospital;
Principal Investigator: Benjamin Echalier
Protocol #17-0423, No Longer Enrolling: 1/6/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03035474
Assess your medical care Help researchers better understand your medical treatment and health outcomes Provide an understanding on how diseases impact your daily life Provide you with more information about heart disease
Principal Investigator: Alicia Gneiting
Protocol #17-6148, No Longer Enrolling: 6/27/2020
Location: Memorial Hospital Central;
Principal Investigator: Amrut Ambardekar
Protocol #17-1343, No Longer Enrolling: 1/15/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02929329
Protocol #17-1506, No Longer Enrolling: 11/14/2019
Location: University of Colorado Hospital;
The objective of this study is to understand real-world treatment patterns, as well as the reasons and barriers for treatment changes in heart failure patients with reduced ejection fraction.
Principal Investigator: Alicia Gneiting
Protocol #16-6062, No Longer Enrolling: 5/20/2020
Location: Memorial Hospital Central;
The purpose of this trial is to establish the safety and efficacy of the Edwards SAPIEN 3 THV device in patients with severe, calcific, aortic stenosis who are at low operative risk for SAVR.
Protocol #16-6069, No Longer Enrolling: 10/1/2019
Locations: Harmony Campus; Medical Center of the Rockies;
More information available at ClinicalTrials.gov: NCT02675114
WATCH-TAVR is a prospective, multicenter, randomized event-driven controlled trial.
Principal Investigator: Darcee Robeson
Protocol #18-6002, No Longer Enrolling: 11/7/2020
Locations: Harmony Campus; Medical Center of the Rockies;
More information available at ClinicalTrials.gov: NCT03173534
The MANAGE-HF study is a multi-center, global, prospective, open label, multi-phase trial. Phase I will be non-randomized. Phase II will be randomized.1) To evaluate and optimize HeartLogic? Heart Failure Diagnostics (called HeartLogic from here on) clinical integration and the alert management process (Phase I) 2. To evaluate HeartLogic in regards to patient outcomes of death and heart failure hospitalizations (Phase II)
Principal Investigator: Janice Huang
Protocol #18-6028, No Longer Enrolling: 5/20/2020
Locations: Memorial Hospital Central; Memorial Hospital North;
More information available at ClinicalTrials.gov: NCT03237858
This study is a prospective, randomized, multi-center, global investigation to determine the safety and effectiveness of the WATCHMAN Device for subjects with non-valvular atrial fibrillation who are deemed not suitable for anticoagulation therapy to reduce the risk of stroke.
Principal Investigator: Brad Mikaelian
Protocol #18-6501, No Longer Enrolling: 1/21/2020
Location: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT02928497
Once the subject meets entry criteria, the study will enroll into a 25 week study. The subject will have subcutaneous injections once weekly and be expected to return to clinic every 6 weeks. The other weekly visits can be done in the subject's location of choice (i.e. home/work). There are multiple blood draws required for this study at certain time points. Other procedures that the subject will complete during the study are: a complete physical exam, EKGs, laboratory assessments, 6 minute walks, 2 right heart caths - one at the beginning and one at the end of the study and daily blood pressures. The subject will be given a home B/P monitor to use. During this study, the subject has a 66% chance of getting active study drug and a 33% change of getting a placebo. Once the subject completes the study, the subject will have the option to enroll into the open label study during which he/she will be given the active study drug.
Protocol #18-0915, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03556020
If you agree to join the study, screening tests will be performed while you are in the hospital to assess your eligibility for the study. If you are eligible to take part in the study, you will be randomized to receive either the study drug or placebo. ?Randomized? means that you will be assigned by chance, like flipping a coin, to take the study drug (CSL112) or the placebo. You will have a 50/50 chance of receiving either CSL112 or placebo. Both the study drug and placebo will be given by intravenous (IV) infusion which means slowly pumping the drug into your body through a small tube that is inserted into a vein. The infusion will last approximately 2 hours. You will receive up to four (4) infusions of either the study drug or placebo weekly for 4 weeks; each infusion is to be given at least 5 days apart. All 4 infusions should be administered within 30 days of you receiving your first infusion. Additional study visits will occur throughout the next year to assess for any new health problems, side effects, or changes in your medical conditions. This is a double-blind study, which means you, your Study Doctor, and the study staff will not know which treatment you are getting, but your Study Doctor can find out if there is an emergency, if it is critical to know for your health, or after the study has ended and the results have been analyzed. Your participation in the study will be approximately 1 year (365 days). This includes the Screening Period (1 visit), an Active Treatment Period (which includes 4 weekly infusion visits and a follow-up visit for safety) and a Follow-Up Period (which includes 5 visits) to assess any new health problems or side effects you may have experienced since your last study visit and your overall well-being. This study will have 11 study visits, 2 of which may be conducted by telephone during the Follow-Up period.
Principal Investigator: James Strader
Protocol #18-6051, No Longer Enrolling: 8/12/2020
Location: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT03473223
Patients diagnosed with an abdominal aortic or aortoiliac aneurysm who are considered candidates for endovascular repair and who meet the study eligibility criteria may be screened for enrollment in the study
Principal Investigator: David Corry
Protocol #19-6501, No Longer Enrolling: 6/24/2020
Location: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT03298477
A Prospective, Multi-Center, Single Arm Study to obtain “Real World” Clinical Data and Characterize the Acute and Long-Term Performance of the Micrusframe and Galaxy Coils for the Endovascular Treatment of Intracranial Aneurysms
Principal Investigator: Rebekah Graner
Protocol #19-6503, No Longer Enrolling: 4/4/2020
Location: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT03642639
The ACTIVE Trial is a prospective, randomized, multicenter trial. Patients with clinically significant functional mitral regurgitation will be randomized 2:1 to receive either transcatheter mitral valve repair with the Edwards Cardioband System plus guideline directed medical therapy (GDMT) or GDMT alone.
Protocol #17-2107, No Longer Enrolling: 11/14/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03016975
The Edwards PASCAL System is intended for the percutaneous reconstruction of an insufficient mitral valve in patients with clinically significant, symptomatic mitral regurgitation and: New York Heart Association (NYHA) Functional Class II, III and ambulatory IV heart failure The primary regurgitant jet is non-commissural. If a secondary jet exists, it must be considered clinically insignificant
Principal Investigator: Gregory Coe
Protocol #18-0876, No Longer Enrolling: 1/6/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03170349
You are being asked to participate in this research study because you have been diagnosed with heart failure and you are implanted with a commercially approved Boston Scientific Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy Defibrillator (CRT-D) device. Inside your device are sensors that monitor your heart failure condition. The purpose of this study is to better understand how sensor readings from your device relate to specific clinical events that you may experience during the time you are in the study. This information may be able to detect when your heart failure is getting worse earlier and with more accuracy. This could help your doctor treat your heart failure timely and with the appropriate treatments.
Principal Investigator: James Strader
Protocol #19-6516, No Longer Enrolling: 8/8/2020
Location: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT03579641
While you are taking part in in the study, you will see your doctor as usual. Your doctor will make notes (medical records) about your disease and its treatment as he/she normally would. For the next 5 years, a study coordinator at your doctor’s office will collect information from your doctor’s notes about your medical condition and treatments, including any medication changes.
Principal Investigator: Rebekah Graner
Protocol #19-6518, No Longer Enrolling: 12/22/2020
Locations: Memorial Hospital Central; Memorial Hospital North;
More information available at ClinicalTrials.gov: NCT04197453
- assess the impact of 13 IV infusions of RSLV-132 on cutaneous lupus disease activity using the CLASI activity score. -assess improvement in disease activity using SLEDAI-2K, BILAG-2004 and PGA; - evaluate the immunogenicity of RSLV-132 in subjects with SLE; - assess improvement in tender or swollen joint count; - assess improvement in patient reported outcomes using the FACIT-Fatigue scale; - assess the ability of subjects to reduce oral steroids at Day 169; ? evaluate the safety and tolerability of 22 weeks of RSLV-132 exposure; - assess the proportion of subjects achieving a 50% improvement in CLASI activity score - assess the following exploratory endpoints -- evaluate the impact of RSLV-132 treatment on gene expression profile; -- evaluate the impact of RSLV-132 treatment on autoantibody and complement profiles; -- evaluate the impact of RSLV-132 on serum protein levels; -- assess the impact of RSLV-132 on the CLASI damage score
Principal Investigator: Susan Boackle
Protocol #16-0603, No Longer Enrolling: 1/4/2020
Locations: Barbara Davis Center; UCD Barbara Davis Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02660944
-To evaluate the efficacy and dose response of evobrutinib (also referred to as M2951) compared to placebo in reducing disease activity in adult subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard of care (SoC) therapy based on SLE Responder Index (SRI)-4 response at Week 52 in all subjects, or on SRI-6 response at Week 52 in the High Disease Activity (HDA) subgroup, defined as SLE Disease Activity Index 2000 (SLEDAI-2K) !Y 10 -To evaluate the safety of M2951 in subjects with SLE on SoC therapy
Principal Investigator: Susan Boackle
Protocol #17-0405, No Longer Enrolling: 1/6/2021
Locations: Barbara Davis Center; UCD Barbara Davis Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02975336
Protocol #17-1792, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03398837
Principal Investigator: Aryeh Fischer
Protocol #17-2000, No Longer Enrolling: 1/6/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03215927
Principal Investigator: Susan Boackle
Protocol #18-0489, No Longer Enrolling: 1/4/2020
Locations: Barbara Davis Center; UCD Barbara Davis Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03161483
Principal Investigator: Karen Franklin
Protocol #18-0907, No Longer Enrolling: 1/4/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03517722
Principal Investigator: Christopher Striebich
Protocol #19-1717, No Longer Enrolling: 4/11/2020
Locations: Barbara Davis Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03994731
Protocol #17-0713, No Longer Enrolling: 11/14/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03110380
Protocol #13-3028, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
The study is being performed in patients with bacterial pneumonia, an infection in the lung[s] to determine how safe the experimental drug, cefiderocol, is and the amount of cefiderocol that is in blood and lung secretion over time (also known as pharmacokinetics or PK). All participants in this study will receive the study drug.
Principal Investigator: Jennifer Maitlen
Protocol #18-1706, No Longer Enrolling: 10/13/2020
Location: University of Colorado Hospital;
Scientists are looking for ways to effectively clear HIV-1 that stays in the body despite successful antiretroviral treatment. Anti-PD-1 is a type of antibody that may target certain cells called latently infected cells where HIV hides and may improve the body's ability to clear these cells, allowing for the possibility of reducing the amount of HIV that persists (the HIV reservoir). This study will include participants who are diagnosed with HIV-1 and suppressed on their current antiretroviral medications.
Protocol #18-2675, No Longer Enrolling: 11/2/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03787095
This study will test an experimental drug named GS-6207 (long acting capsid inhibitor) in combination with other HIV medications for the treatment of human immunodeficiency virus (HIV) infection. An experimental drug means that it is not yet approved for the treatment of HIV-1 Infection by the United States Food and Drug Administration (FDA) and your country’s regulatory agency. Other HIV medications included in this study are B/F/TAF (Biktarvy?) and, F/TAF (Descovy?), which are currently approved by the U.S. FDA for the treatment of HIV infection and TAF (VEMLIDY?) and Bictegravir (BIC) which are part of the medication Biktarvy but are not currently approved as a single agent HIV medication by the U.S. FDA. This is a randomized, open label study. Open-label means you and your study doctor will know what study drugs you will be taking. Randomized means the study treatment you take will be chosen by chance (like flipping a coin) to receive one of four study treatments. The randomization for this study is in a 2:2:2:1 ratio. You will have 6 out of 7 chances to receive GS-6207 in combination with other HIV medications and a 1 out of 7 chance to receive B/F/TAF.
Principal Investigator: Suzanne Fiorillo
Protocol #19-2810, No Longer Enrolling: 9/26/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04143594
Principal Investigator: Suzanne Fiorillo
Protocol #20-0615, No Longer Enrolling: 9/24/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04315298
Principal Investigator: Suzanne Fiorillo
Protocol #20-0616, No Longer Enrolling: 1/7/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04292899
To estimate the efficacy, safety, tolerability and reactogenicity of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19 in adults. To see if you qualify for the study, please visit this webpage: http://bit.ly/covid19vaccinestudy
Principal Investigator: Gary Luckasen
Protocol #20-9990, No Longer Enrolling: 2/23/2021
Locations: Greeley Campus; Medical Center of the Rockies; Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT04516746
Assessment of dapagliflozin vs. placebo to slow the progression of kidney disease in patients with chronic kidney disease (CKD). Participation is expected to last between 1.5-4 years with 9-17 visits during that time. Compensation is provided.
Protocol #17-0412, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03036150
Protocol #17-1812, No Longer Enrolling: 10/18/2019
Location: University of Colorado Hospital;
The study is a multicenter, prospective, double-blind, randomized, placebo-controlled, pivotal registration study. The Sponsor, Investigators and patients will all be blinded to study drug assignment. Patients in this study are at risk for requiring dialysis in the first week following transplantation of a kidney from a deceased donor and have early clinical indication of DGF based on poor renal function post-transplantation. Patients who fulfill all other eligibility criteria will be randomized in a 1:1 fashion to receive 2 mg/kg ANG-3777 or placebo (normal saline).Primary Objective: ? To demonstrate the safety and efficacy of ANG-3777 in reducing the severity of delayed graft function (DGF) in recipients at high risk of DGF after receiving a deceased donor renal allograft with DGF Secondary Objectives: ? To demonstrate the efficacy of ANG-3777 in optimizing renal function in recipients of a deceased donor renal allograft with DGF ? To demonstrate the efficacy of ANG-3777 in reducing length of hospital stay in recipients of a deceased donor renal allograft with DGF
Principal Investigator: James Cooper
Protocol #16-1038, No Longer Enrolling: 10/2/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02474667
Protocol #17-0275, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02547220
Evaluation of safety, efficacy and immunosuppression (IS) therapy following FCR001 cell therapy after kidney transplant vs. standard of care. FCR001 is a novel, cryopreserved allogeneic somatic cell therapy, derived from mobilized peripheral blood mononuclear cells from the same donor as the allograft, and containing hematopoietic progenitor cells, facilitating cells and alpha beta T cells. The rationale is to establish durable chimerism and donor-specific tolerance in the recipient enabling freedom from chronic IS and its associated toxicities.Primary Objective: To evaluate the proportion of FCR001 recipients who are free from IS, without biopsy-proven acute rejection (BPAR), at 24 months posttransplant. Key Secondary Objective: To evaluate the change in renal function (estimated glomerular filtration rate [eGFR] by Modification of Diet in Renal Disease (MDRD4) from post-transplant baseline (Month 1) to Month 24 in FCR001 recipients.
Principal Investigator: Alexander Wiseman
Protocol #19-1299, No Longer Enrolling: 9/30/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03995901
Principal Investigator: Anna Klochak
Protocol #17-2311, No Longer Enrolling: 10/21/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT04156204
Principal Investigator: Bradley Dixon
Protocol #18-0225, No Longer Enrolling: 3/26/2020
Location: Childrens Hospital Colorado;
Principal Investigator: Anna Klochak
Protocol #18-2100, No Longer Enrolling: 8/1/2020
Location: Childrens Hospital Colorado;
Principal Investigator: Anna Klochak
Protocol #17-2378, No Longer Enrolling: 2/20/2021
Location: Childrens Hospital Colorado;
Principal Investigator: Anna Klochak
Protocol #18-1723, No Longer Enrolling: 6/24/2020
Location: Childrens Hospital Colorado;
Each study subject will be randomized to receive either study drug or a placebo for 6 months. Neither the subject nor the study staff will know which treatment was given until after the study has finished. Study subjects will be monitored every 2 weeks for the first month, then less frequently as the study progresses. The total length of the study is about 8 months.
Principal Investigator: Judith Blaine
Protocol #19-2819, No Longer Enrolling: 9/25/2020
Locations: Renal Research Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03373461
Principal Investigator: Anna Klochak
Protocol #19-2333, No Longer Enrolling: 2/9/2021
Location: Childrens Hospital Colorado;
The goal of this study is to learn more about how brain function drives binge eating, a condition where individuals eat unhealthy large amounts of food
Protocol #16-2658, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03393039
Principal Investigator: Elizabeth Thomas
Protocol #18-0487, No Longer Enrolling: 2/27/2020
Locations: Anschutz Health and Wellness; UCD Anschutz Health & Wellness Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03571048
The primary objectives of this study are: - to compare the efficacy of basiliximab induction, ASKP1240, mycophenolate mofetil [MMF], and steroids to the standard of care immunosuppressive regimen (basiliximab induction + tacrolimus + MMF + steroids) [CNI avoidance]. - to compare the efficacy of basiliximab induction, ASKP1240, tacrolimus, and steroids to the standard of care immunosuppressive regimen (basiliximab induction + tacrolimus + MMF + steroids) [CNI minimization- MMF avoidance]. The secondary objectives of this study are: - to compare the safety of the experimental arms to the standard of care arm. -to evaluate the long term safety and tolerability of ASKP1240 administration in subjects in the Long Term Extension (LTE) period of the study.
Protocol #13-0061, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01780844
This study plans to learn more about breast cancer in young women, including the biology of the disease and young women's experiences with it. We aim to use this information to improve the care and information available for young women with breast cancer.
Principal Investigator: Virginia Borges
Protocol #08-1222, No Longer Enrolling: 2/12/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01468246
Principal Investigator: Claire Cofer
Protocol #07-0354, No Longer Enrolling: 2/13/2021
;
Protocol #11-1248, No Longer Enrolling: 10/24/2019
;
Principal Investigator: Cyndi Long
Protocol #12-0144, No Longer Enrolling: 1/6/2021
;
Protocol #12-1525, No Longer Enrolling: 11/1/2019
;
Protocol #12-1557, No Longer Enrolling: 11/1/2019
;
Protocol #13-0101, No Longer Enrolling: 11/1/2019
;
Protocol #13-2952, No Longer Enrolling: 10/24/2019
;
Principal Investigator: Evalina Burger-Van der Walt
Protocol #14-1971, No Longer Enrolling: 1/6/2021
;
Protocol #14-0884, No Longer Enrolling: 10/24/2019
;
Principal Investigator: Alyse Brennecke
Protocol #15-1397, No Longer Enrolling: 11/23/2019
Location: University of Colorado Hospital;
Protocol #15-1676, No Longer Enrolling: 10/22/2019
;
Principal Investigator: Adam Green
Protocol #15-1621, No Longer Enrolling: 3/10/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02992015
Protocol #15-2069, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
Principal Investigator: Gwendolyn Wade
Protocol #15-2078, No Longer Enrolling: 1/17/2020
Locations: Greeley Hospital; Harmony Campus; Medical Center of the Rockies; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02308085
Principal Investigator: Michael Verneris
Protocol #15-2279, No Longer Enrolling: 11/28/2019
;
In this study we are looking at how the brain works in people who have dystonia compared to those who don't have dystonia. This study will use magnetic resonance imaging (MRI), magnetoencephalography (MEG), and Electroencephalography (EEG) to see how the brain reacts while resting and doing a finger-tapping task. Aim 1: A second level contrast between Primary Focal Dystonia (PFD) and Healthy Controls (HC) of the statistical parametric maps of correlation coefficients at rest and during a tapping motor task Aim 2: the strength of correlation between basal ganglia motor network functional connectivity measures and total PFD clinical assessment scale scores
Principal Investigator: Brian Berman
Protocol #12-0289, No Longer Enrolling: 2/4/2021
Locations: Colorado Research Center; Department Specific Free Standing Clinic; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01761903
Protocol #15-0963, No Longer Enrolling: 10/22/2019
;
Protocol #15-1187, No Longer Enrolling: 10/22/2019
;
Protocol #15-1106, No Longer Enrolling: 10/22/2019
;
Protocol #16-1023, No Longer Enrolling: 11/7/2019
Location: University of Colorado Hospital;
Principal Investigator: Gwendolyn Wade
Protocol #16-0705, No Longer Enrolling: 9/22/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02779751
Principal Investigator: KELLY MALONEY
Protocol #16-0907, No Longer Enrolling: 11/23/2019
Location: Childrens Hospital Colorado;
Protocol #16-1082, No Longer Enrolling: 10/18/2019
Location: University of Colorado Hospital;
To collect archival tissues and validated clinical history of deceased Lung cancer patients & deposit them into the NCI SPORE biobank
Principal Investigator: DANIEL MERRICK
Protocol #15-1294, No Longer Enrolling: 11/23/2019
Locations: Department Specific Free Standing Clinic; University of Colorado Cancer Center;
Principal Investigator: Tim Garrington
Protocol #15-2393, No Longer Enrolling: 5/22/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02484443
Protocol #14-2270, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02378883
Protocol #15-0461, No Longer Enrolling: 11/9/2019
Locations: Boulder Health Center; Cherry Creek Medical Center; Greeley Hospital; Harmony Campus; Lone Tree Medical Center; Longs Peak Hospital; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Pikes Peak Regional Hospital; Poudre Valley Hospital; Steadman Hawkins Clinic - Denver; UCHealth Internal Medical Clinic - Lowry; UCHealth Stapleton Medical Center; University of Colorado Hospital;
1. To determine which pharmaceutical therapy is most effective and causes the fewest side effects in CSPN. 2. To determine which drug has the fewest and which has the most side effects.
Protocol #14-2157, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
Principal Investigator: Carmen Rivera
Protocol #16-1285, No Longer Enrolling: 4/15/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02304458
To obtain whole blood specimens from pregnant subjects to be used for research and development and clinical validation studies of prenatal assays.
Principal Investigator: Chloe Banel
Protocol #16-0911, No Longer Enrolling: 1/21/2021
Locations: Childrens Hospital Colorado; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02430584
Principal Investigator: D. Ryan Ormond
Protocol #16-0908, No Longer Enrolling: 11/23/2019
Location: University of Colorado Hospital;
Principal Investigator: D. Ryan Ormond
Protocol #16-0895, No Longer Enrolling: 11/23/2019
Location: University of Colorado Hospital;
Principal Investigator: Deb Schissel
Protocol #16-0932, No Longer Enrolling: 11/19/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02868268
Protocol #16-1541, No Longer Enrolling: 11/20/2019
Location: University of Colorado Hospital;
Principal Investigator: Jenna Sopfe
Protocol #16-1496, No Longer Enrolling: 11/23/2019
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03482154
Principal Investigator: Elissa Kolva
Protocol #16-1714, No Longer Enrolling: 11/23/2019
Location: University of Colorado Hospital;
Principal Investigator: Ellen Lyon
Protocol #15-1309, No Longer Enrolling: 12/27/2019
Locations: CTRC-adult; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02544321
Protocol #15-1348, No Longer Enrolling: 10/1/2019
;
More information available at ClinicalTrials.gov: NCT02208440
Principal Investigator: Darren Lynn
Protocol #16-1782, No Longer Enrolling: 10/8/2020
Location: University of Colorado Hospital;
Principal Investigator: E. David Crawford
Protocol #16-2525, No Longer Enrolling: 11/23/2019
Location: University of Colorado Hospital;
Protocol #16-1884, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Protocol #16-1983, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Principal Investigator: Ellen Lyon
Protocol #11-0693, No Longer Enrolling: 12/27/2019
Locations: CTRC-adult; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01813929
Protocol #06-0062, No Longer Enrolling: 10/1/2019
Locations: CTRC-adult; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01793909
Protocol #13-2015, No Longer Enrolling: 10/4/2019
Location: CTRC-adult;
More information available at ClinicalTrials.gov: NCT01951339
Principal Investigator: Anosheh Afghahi
Protocol #16-2276, No Longer Enrolling: 11/23/2019
;
Principal Investigator: Bryan Haugen
Protocol #16-0868, No Longer Enrolling: 11/23/2019
Location: University of Colorado Hospital;
Principal Investigator: Gwendolyn Wade
Protocol #16-2437, No Longer Enrolling: 12/5/2020
Locations: Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Lone Tree Medical Center; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02927249
Principal Investigator: Elizabeth Chick
Protocol #16-2448, No Longer Enrolling: 9/30/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03392142
Protocol #16-2487, No Longer Enrolling: 10/24/2019
Location: University of Colorado Hospital;
Principal Investigator: Anthony Elias
Protocol #16-2594, No Longer Enrolling: 8/26/2020
Locations: Greeley Campus; Harmony Campus; Highlands Ranch Hospital; Lone Tree Medical Center; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02954874
Principal Investigator: MARY JACKSON
Protocol #16-2160, No Longer Enrolling: 11/23/2019
Locations: Rocky Mountain Regional VA Medical Center; University of Colorado Hospital;
Protocol #16-2755, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Protocol #15-2242, No Longer Enrolling: 1/15/2021
;
Principal Investigator: SACHIN WANI
Protocol #16-2636, No Longer Enrolling: 11/26/2019
Location: University of Colorado Hospital;
Protocol #17-0192, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
Principal Investigator: ASHLEY GLODE
Protocol #16-2228, No Longer Enrolling: 11/26/2019
Location: University of Colorado Hospital;
Protocol #14-1505, No Longer Enrolling: 10/4/2019
Location: University of Colorado Hospital;
This study plans to learn more about immune responses in intestinal (gut) tissue in people with human immunodeficiency virus (HIV) infection. This study will determine whether change in the composition of gut bacteria in HIV infected individuals is related to a high prevalence of chronic gut inflammation and metabolic disease. The investigators will also investigate immune-modulatory properties of specific bacteria that correlate with disease both by characterizing which functional genes are selected for in their genomes and by stimulating immune cells isolated from blood and gut tissue with bacterial isolates. This work will establish whether gain/loss of bacterial drivers/suppressors of information in the gut contributes to metabolic disease in HIV-infected individuals.
Protocol #14-1595, No Longer Enrolling: 10/4/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02258685
The investigators hypothesize that neutrophils and monocytes developed under the influence of Interferon- gamma-1b (IFN-gamma-1b, Actimmune(R) in vivo will display enhanced function across a broad range of activities related in large part to the transcriptional activation effects of this cytokine. The investigators will evaluate the effects of IFN-? in healthy human subjects in vivo on gene expression, biologic activity markers, and functional activity of myeloid cells in single dose studies and in steady state studies.
Protocol #15-1643, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02609932
The primary objective of this proposal is to compare a moderate or high intensity exercise intervention to improve physical function in persons aging with Human Immunodeficiency Virus (HIV).
Protocol #14-2207, No Longer Enrolling: 10/4/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02404792
Principal Investigator: Elizabeth Mcfarland
Protocol #16-1564, No Longer Enrolling: 12/17/2019
;
1. To establish the relationship between exposure to certain female factors (e.g. contraceptive, menstrual, pregnancy and sexual history) and the presence of serum RA-related autoimmunity and/or RA-related immunologic factors in subjects with RA, subjects at-risk for RA, and control subjects. These evaluations will include baseline and longitudinal studies to determine incident development of RA-related autoimmunity. 2. To determine the prevalence of RA-related biomarkers, such as Abs and inflammatory cytokines, in the lower female genital tract in women with RA, women at-risk for RA, and controls. These evaluations will include baseline and longitudinal studies to determine incident development of RA-related autoimmunity at the CV mucosa. 3. To evaluate microbial communities in the lower female genital tract of women with RA, women at-risk for RA, and control subjects. These evaluations will include baseline and longitudinal studies of microbiota as well as comparison to serum and CV biomarkers. 4. To simultaneously compare RA-related Abs and immunologic biomarkers in the female genital tract and serum in women with RA, women at-risk for RA and control subjects. These evaluations include cross-sectional and longitudinal studies to determine evolution over time at each site (CV fluid and serum) to determine incident development of RA-related autoimmunity. 5. To demonstrate specific immunologic mechanisms of RA-related Ab generation in the cervical and uterine mucosa associated with systemic or mucosal RA-related Abs in women who had previously obtained and stored cervical or uterine tissue. 6. To compare the performance of self-collected and investigator-collected CV samples for detection of mucosal immunity and microbiota.
Protocol #14-1751, No Longer Enrolling: 10/4/2019
Location: University of Colorado Hospital;
The goal of this study is to determine whether the use of the PSS with Truvada will vary the drug concentrations of FTC/TDF.
Protocol #16-1478, No Longer Enrolling: 10/16/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02968576
The overall goal of this pilot project is to take the first steps toward developing translational methods to investigate links between changes in energy flux and the circadian system in human tissues.
Principal Investigator: Corey Rynders
Protocol #15-1570, No Longer Enrolling: 12/27/2019
Locations: CTRC-adult; Denver Health Medical Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02809482
Determine the efficacy of the EnteroTracker String Test (EST)for monitoring inflammation in the esophagus. Compare analysis of the EST to biopises taken during an upper endoscopy.
Principal Investigator: Faria Ahmed
Protocol #07-0223, No Longer Enrolling: 12/31/2019
Locations: Childrens Hospital Colorado; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02008903
Principal Investigator: Deirdre Appelhans
Protocol #16-2747, No Longer Enrolling: 3/10/2020
Location: Childrens Hospital Colorado;
Principal Investigator: Barb Shepperd
Protocol #17-0486, No Longer Enrolling: 1/22/2021
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02717507
Principal Investigator: Anosheh Afghahi
Protocol #17-0763, No Longer Enrolling: 11/26/2019
Location: University of Colorado Hospital;
Protocol #16-0604, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02260934
Principal Investigator: Andrew Monte
Protocol #14-0381, No Longer Enrolling: 10/9/2020
Location: University of Colorado Hospital;
Principal Investigator: Ellen Burnham
Protocol #15-1799, No Longer Enrolling: 12/28/2019
Locations: CTRC-adult; University of Colorado Hospital;
Principal Investigator: Petter Bjornstad
Protocol #15-0541, No Longer Enrolling: 12/27/2019
Locations: CTRC-adult; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02502071
Protocol #17-0365, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Principal Investigator: Viral Shah
Protocol #15-1854, No Longer Enrolling: 9/18/2020
Location: University of Colorado Hospital;
Protocol #17-0666, No Longer Enrolling: 11/7/2019
Location: Childrens Hospital Colorado;
Protocol #17-0722, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02989610
Protocol #17-0215, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
Principal Investigator: KELLY MALONEY
Protocol #17-0791, No Longer Enrolling: 12/2/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02774850
Principal Investigator: KELLY MALONEY
Protocol #17-0812, No Longer Enrolling: 6/24/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02777021
Principal Investigator: Thomas Schroeppel
Protocol #17-6150, No Longer Enrolling: 5/20/2020
Location: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT02960854
Protocol #17-1041, No Longer Enrolling: 11/7/2019
Location: University of Colorado Hospital;
Protocol #17-0784, No Longer Enrolling: 10/5/2019
Location: University of Colorado Hospital;
The primary objective of this registry is to determine the procedure related mortality associated with the use of the Angiovac device. This is a FDA approved device, being used in clinical practice for the removal of fresh, soft thrombi or emboli during extracorporeal bypass for up to 6 hours.
Principal Investigator: Paul Rochon
Protocol #15-1608, No Longer Enrolling: 11/6/2020
Location: University of Colorado Hospital;
Principal Investigator: Bradley Corr
Protocol #17-1222, No Longer Enrolling: 11/26/2019
Location: University of Colorado Hospital;
Protocol #17-0734, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03160898
Principal Investigator: Eileen Axibal
Protocol #17-1307, No Longer Enrolling: 11/26/2019
Location: University of Colorado Hospital;
Protocol #17-1136, No Longer Enrolling: 10/18/2019
Location: University of Colorado Hospital;
Principal Investigator: Chanel Mansfield
Protocol #16-1748, No Longer Enrolling: 5/2/2020
Location: University of Colorado Hospital;
Protocol #16-1074, No Longer Enrolling: 11/14/2019
Location: University of Colorado Hospital;
Principal Investigator: Nicole Draper
Protocol #17-1336, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Protocol #17-0850, No Longer Enrolling: 11/1/2019
Location: University of Colorado Hospital;
Principal Investigator: Robert Eckel
Protocol #15-1412, No Longer Enrolling: 1/6/2021
Location: University of Colorado Hospital;
Protocol #17-1004, No Longer Enrolling: 11/7/2019
Location: University of Colorado Hospital;
Protocol #17-1267, No Longer Enrolling: 11/2/2019
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02562235
Protocol #16-2414, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Principal Investigator: Julie Dunn
Protocol #17-6191, No Longer Enrolling: 3/3/2021
Location: Medical Center of the Rockies;
Accuracy of the software will be evaluated through case review. The cases entered into the Lifeboard software will be compared to the paper trauma flow sheet. Research staff will be comparing what is entered into the software on the tablet against the trauma flow sheet for each case.
Principal Investigator: Julie Dunn
Protocol #UCH14-1326, No Longer Enrolling: 1/6/2021
Location: Medical Center of the Rockies;
Protocol #UCH11-0510, No Longer Enrolling: 10/1/2019
Location: Memorial Hospital Central;
Protocol #UCH11-0716, No Longer Enrolling: 10/1/2019
Location: Memorial Hospital Central;
Principal Investigator: Caralyn Henderson
Protocol #UCH14-0104, No Longer Enrolling: 5/19/2020
Location: Memorial Hospital Central;
Protocol #UCH07-0207, No Longer Enrolling: 10/1/2019
Location: Memorial Hospital Central;
Protocol #UCH10-0821, No Longer Enrolling: 10/1/2019
Location: Memorial Hospital Central;
Protocol #UCH11-1023, No Longer Enrolling: 10/1/2019
Location: Memorial Hospital Central;
Protocol #UCH09-0308, No Longer Enrolling: 10/1/2019
Location: Memorial Hospital Central;
Protocol #UCH11-0715, No Longer Enrolling: 10/1/2019
Location: Memorial Hospital Central;
Protocol #17-0380, No Longer Enrolling: 11/1/2019
Locations: Memorial Hospital Central; Memorial Hospital North;
Protocol #UCH09-1018, No Longer Enrolling: 10/1/2019
Location: Memorial Hospital Central;
Protocol #UCH06-0629, No Longer Enrolling: 10/1/2019
Location: Memorial Hospital Central;
Protocol #UCH07-0623, No Longer Enrolling: 10/1/2019
Location: Memorial Hospital Central;
Protocol #UCH06-0730, No Longer Enrolling: 10/1/2019
Location: Memorial Hospital Central;
Protocol #UCH02-1026, No Longer Enrolling: 10/1/2019
Location: Memorial Hospital Central;
Principal Investigator: Paul Reckard
Protocol #17-6199, No Longer Enrolling: 5/19/2020
Location: Memorial Hospital Central;
More information available at ClinicalTrials.gov: NCT03095006
Protocol #16-1551, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
To compare PFS between ribociclib in combination with fulvestrant to placebo in combination with fulvestrant among postmenopausal women with HR+, HER2-negative advanced breast cancer who received no or only one prior endocrine treatment for advanced disease
Principal Investigator: Steven Schuster
Protocol #15-6019, No Longer Enrolling: 1/29/2020
Locations: Greeley Hospital; Harmony Campus; Medical Center of the Rockies; Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT02422615
Protocol #16-6057, No Longer Enrolling: 10/1/2019
Locations: Greeley Hospital; Harmony Campus; Medical Center of the Rockies; Poudre Valley Hospital;
Principal Investigator: Scott Kaczkowski
Protocol #UCH12-1142, No Longer Enrolling: 5/20/2020
;
Principal Investigator: Scott Kaczkowski
Protocol #UCH13-1272, No Longer Enrolling: 5/20/2020
;
Principal Investigator: Megan Lechner
Protocol #15-6021, No Longer Enrolling: 1/6/2021
Location: Memorial Hospital Central;
Principal Investigator: Steven Schuster
Protocol #UCH04-680, No Longer Enrolling: 5/20/2020
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Poudre Valley Hospital;
More information available at ClinicalTrials.gov: NCT00975676
Protocol #UCH13-1260, No Longer Enrolling: 11/7/2019
Locations: Greeley Hospital; Harmony Campus; Medical Center of the Rockies; Poudre Valley Hospital;
Principal Investigator: Tim Garrington
Protocol #17-2472, No Longer Enrolling: 12/2/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03206450
Compassionate use of Lorcaserin in Dravet Syndrome
Protocol #14-2440, No Longer Enrolling: 10/1/2019
Location: Childrens Hospital Colorado;
Principal Investigator: Thomas Schroeppel
Protocol #17-6220, No Longer Enrolling: 5/20/2020
Location: Memorial Hospital Central;
Principal Investigator: Thomas Schroeppel
Protocol #18-6038, No Longer Enrolling: 5/20/2020
Location: Memorial Hospital Central;
Principal Investigator: Taizo Nakano
Protocol #18-0524, No Longer Enrolling: 11/26/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT02845596
Protocol #16-0996, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
Principal Investigator: Mercedes Zirbes
Protocol #13-2415, No Longer Enrolling: 5/2/2020
;
Principal Investigator: Michael Verneris
Protocol #18-0834, No Longer Enrolling: 3/2/2021
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03475212
Protocol #15-2421, No Longer Enrolling: 10/1/2019
Location: Childrens Hospital Colorado;
Principal Investigator: Carmen Rivera
Protocol #18-0947, No Longer Enrolling: 4/18/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03387020
Principal Investigator: LEAH SCHUBERT
Protocol #18-1073, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Lisa Ferrigno
Protocol #18-1095, No Longer Enrolling: 4/7/2020
Locations: Memorial Hospital Central; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03403751
Protocol #18-1031, No Longer Enrolling: 10/31/2019
Location: University of Colorado Hospital;
Protocol #18-1096, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Protocol #18-1143, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Protocol #18-0795, No Longer Enrolling: 11/1/2019
Locations: Childrens Hospital Colorado; University of Colorado Hospital;
Protocol #18-1176, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Principal Investigator: James DeGregori
Protocol #18-1227, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Protocol #18-1251, No Longer Enrolling: 11/7/2019
Location: University of Colorado Hospital;
Principal Investigator: Lauren Fishbein
Protocol #18-1240, No Longer Enrolling: 11/28/2019
Locations: Childrens Hospital Colorado; University of Colorado Hospital;
Principal Investigator: Gretchen Ahrendt
Protocol #18-1123, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Matthew Rioth
Protocol #18-1084, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Protocol #18-1177, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Protocol #18-2184, No Longer Enrolling: 10/31/2019
Locations: Lone Tree Medical Center; University of Colorado Hospital;
Protocol #07-0084, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Protocol #17-0640, No Longer Enrolling: 10/18/2019
Location: University of Colorado Hospital;
Protocol #18-2263, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Principal Investigator: Joanna Huang
Protocol #18-2186, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Tiba Al Sagheer
Protocol #18-2272, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Jenna Sopfe
Protocol #18-2257, No Longer Enrolling: 11/28/2019
Location: Childrens Hospital Colorado;
Principal Investigator: Eric Rosen
Protocol #18-2077, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Cathy Bradley
Protocol #18-2442, No Longer Enrolling: 11/28/2019
Location: University of Colorado Cancer Center;
Principal Investigator: Derek Schatz
Protocol #18-2461, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: James DeGregori
Protocol #18-2584, No Longer Enrolling: 11/28/2019
Location: Rocky Mountain Regional VA Medical Center;
Protocol #18-2499, No Longer Enrolling: 10/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Samy Youssef
Protocol #18-2590, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Laura Cannon
Protocol #18-2701, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Courtney Holmes
Protocol #18-6128, No Longer Enrolling: 5/20/2020
Location: Memorial Hospital Central;
Protocol #18-2699, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Principal Investigator: Sarah Tevis
Protocol #18-2828, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Protocol #18-2840, No Longer Enrolling: 11/19/2019
Location: University of Colorado Hospital;
Protocol #18-2887, No Longer Enrolling: 10/30/2019
Location: University of Colorado Hospital;
Protocol #19-0522, No Longer Enrolling: 10/23/2019
Location: University of Colorado Hospital;
Protocol #19-0693, No Longer Enrolling: 11/1/2019
Location: University of Colorado Hospital;
Protocol #19-0653, No Longer Enrolling: 10/28/2019
Location: University of Colorado Hospital;
Protocol #19-0950, No Longer Enrolling: 11/16/2019
Location: University of Colorado Hospital;
Protocol #19-6064, No Longer Enrolling: 10/1/2019
Locations: Harmony Campus; Medical Center of the Rockies; Poudre Valley Hospital;
Protocol #19-0973, No Longer Enrolling: 11/1/2019
Location: University of Colorado Hospital;
Principal Investigator: Edin Nevzati
Protocol #19-1028, No Longer Enrolling: 12/28/2019
Location: University of Colorado Hospital;
Protocol #19-1089, No Longer Enrolling: 11/7/2019
Location: University of Colorado Hospital;
Protocol #19-1136, No Longer Enrolling: 11/7/2019
;
Protocol #13-2571, No Longer Enrolling: 10/1/2019
Location: Childrens Hospital Colorado;
Protocol #19-1306, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Protocol #19-1465, No Longer Enrolling: 10/31/2019
Location: University of Colorado Hospital;
Protocol #19-1388, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
Protocol #13-2797, No Longer Enrolling: 10/4/2019
Location: Childrens Hospital Colorado;
Protocol #19-1495, No Longer Enrolling: 10/1/2019
Location: University of Colorado Hospital;
Principal Investigator: Derek Schatz
Protocol #18-1461, No Longer Enrolling: 1/6/2021
Location: University of Colorado Hospital;
Protocol #17-1414, No Longer Enrolling: 11/7/2019
Location: Colorado Research Center;
Protocol #17-1411, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Protocol #17-1591, No Longer Enrolling: 11/7/2019
Location: University of Colorado Hospital;
Principal Investigator: Valerie Slegesky
Protocol #17-1378, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Jesse Roberts
Protocol #17-1401, No Longer Enrolling: 11/28/2019
Location: Childrens Hospital Colorado;
Principal Investigator: Chris Rivard
Protocol #17-1798, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Philip Owens
Protocol #17-1733, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Protocol #17-1942, No Longer Enrolling: 10/19/2019
Location: University of Colorado Hospital;
Principal Investigator: Kian Behbakht
Protocol #17-1794, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Benjamin Bitler
Protocol #18-0119, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Protocol #17-1753, No Longer Enrolling: 10/18/2019
Location: University of Colorado Hospital;
Protocol #17-1763, No Longer Enrolling: 10/18/2019
Location: University of Colorado Hospital;
Protocol #18-0079, No Longer Enrolling: 10/1/2019
Location: Childrens Hospital Colorado;
Protocol #17-2115, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Protocol #17-2116, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Principal Investigator: Fuyong Xing
Protocol #17-2167, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Amanda Saltzman
Protocol #17-2142, No Longer Enrolling: 11/28/2019
Location: Childrens Hospital Colorado;
Protocol #18-0080, No Longer Enrolling: 11/7/2019
Location: University of Colorado Hospital;
Protocol #18-0023, No Longer Enrolling: 11/14/2019
Location: University of Colorado Hospital;
Principal Investigator: Benjamin Bitler
Protocol #17-7788, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Protocol #18-0081, No Longer Enrolling: 11/7/2019
Location: University of Colorado Hospital;
Principal Investigator: Eric Rosen
Protocol #18-0094, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Arthur Liu
Protocol #18-0201, No Longer Enrolling: 11/28/2019
Locations: Childrens Hospital Colorado; University of Colorado Hospital;
Protocol #18-0357, No Longer Enrolling: 11/7/2019
Location: University of Colorado Hospital;
Principal Investigator: Peter Witt
Protocol #18-0335, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Protocol #18-0409, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Principal Investigator: Hilary Van Noort
Protocol #18-0515, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Yuli Chen
Protocol #18-0528, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Protocol #18-0597, No Longer Enrolling: 10/18/2019
Locations: University of Colorado Hospital; University of Southern California;
Protocol #18-0636, No Longer Enrolling: 10/31/2019
Location: University of Colorado Hospital;
Principal Investigator: Mariah Brown
Protocol #18-0596, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Katherine Sabourin
Protocol #18-0749, No Longer Enrolling: 11/28/2019
;
Principal Investigator: Bonnie Gance-Cleveland
Protocol #18-0263, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Hilary Van Noort
Protocol #18-0717, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Hilary Van Noort
Protocol #18-0726, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Protocol #18-0748, No Longer Enrolling: 10/18/2019
Location: University of Colorado Hospital;
Principal Investigator: Alexandra Suttman
Protocol #18-0598, No Longer Enrolling: 11/28/2019
Location: Childrens Hospital Colorado;
Protocol #18-0776, No Longer Enrolling: 10/25/2019
Location: University of Colorado Hospital;
Principal Investigator: Elizabeth Chick
Protocol #18-1383, No Longer Enrolling: 11/28/2019
Location: Childrens Hospital Colorado;
Principal Investigator: Matthew Rioth
Protocol #18-0848, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Roger Giller
Protocol #18-1420, No Longer Enrolling: 11/28/2019
Location: Childrens Hospital Colorado;
Protocol #18-1278, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Protocol #18-1277, No Longer Enrolling: 11/7/2019
Location: University of Colorado Hospital;
Principal Investigator: Sherry Osceola
Protocol #18-1453, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Protocol #18-1720, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Protocol #18-1732, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Principal Investigator: Kendra Conzen
Protocol #18-1708, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: AMY KEATING
Protocol #18-1943, No Longer Enrolling: 11/28/2019
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03601442
Principal Investigator: MIRIAM POST
Protocol #18-1898, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Jean Mulcahy-Levy
Protocol #18-1815, No Longer Enrolling: 11/28/2019
Location: Childrens Hospital Colorado;
Principal Investigator: Eric Rosen
Protocol #18-1634, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Myles Cockburn
Protocol #18-1987, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Principal Investigator: Clay Smith
Protocol #18-1861, No Longer Enrolling: 11/28/2019
Location: University of Colorado Hospital;
Protocol #19-2297, No Longer Enrolling: 11/1/2019
Location: Childrens Hospital Colorado;
Protocol #19-1766, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Principal Investigator: Carlyne Cool
Protocol #19-1742, No Longer Enrolling: 12/24/2019
Location: University of Colorado Hospital;
Protocol #19-1970, No Longer Enrolling: 10/22/2019
Location: University of Colorado Hospital;
Protocol #18-1940, No Longer Enrolling: 11/1/2019
Location: Childrens Hospital Colorado;
This is a pilot study evaluating the effect of uric acid lowering by a single dose of pegloticase (a uricase) on markers of cardiovascular and renal health in ten young men ages 18-25 years with youth-onset type 2 diabetes (diagnosed at less than 21 years of age) over 7 days. Previous research has shown that young adults with youth-onset type 2 diabetes have a high prevalence of elevated levels of uric acid in the blood, and this elevated uric acid strongly predicts development of high blood pressure and diabetic kidney disease over 7 years. By reducing uric acid levels in the blood, we aim to evaluate changes in markers of early cardiovascular and kidney disease over 1 week in participants.
Principal Investigator: Amy Rydin
Protocol #18-1700, No Longer Enrolling: 11/22/2019
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT03899883
Principal Investigator: Rachael Burnett
Protocol #19-0159, No Longer Enrolling: 8/15/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03614260
This is a Phase 2a, randomized, open-label, active control, multi-center study to assess the efficacy and safety of bleselumab in preventing the rFSGS in de novo kidney transplant subjects.Primary Objective: - To assess the efficacy of the bleselumab regimen (basiliximab induction, tacrolimus, steroids and bleselumab) compared with the SOC regimen (basiliximab induction, tacrolimus, steroids and MMF) in the prevention of the recurrence of focal segmental glomerulosclerosis (rFSGS) defined as nephrotic range proteinuria with proteincreatinine ratio (> or equal to 3.0 g/g) through 3 months post-transplant. Death, graft loss or lost to follow-up will be imputed as rFSGS. Secondary Objectives: - To assess the incidence of nephrotic range proteinuria with protein-creatinine ratio (> or equal to 3.0 g/g) through 6 and 12 months post-transplant. Death, graft loss or lost to follow-up will be imputed as rFSGS. - To assess the incidence of biopsy-proven acute rejection (BPAR, Banff Grade ≥ 1; local read) through 3, 6 and 12 months post-transplant. - To assess the incidence of efficacy failure defined as BPAR (Banff Grade ≥ 1; local read), death, graft loss or lost to follow-up through 12 months post-transplant. - To assess the incidence of biopsy-proven (blinded, central read) rFSGS through 3, 6 and 12 months post-transplant. - To assess the safety of the bleselumab regimen compared with the SOC regimen.
Principal Investigator: Alexander Wiseman
Protocol #17-1010, No Longer Enrolling: 10/10/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02921789
Principal Investigator: Jing Wang
Protocol #16-2436, No Longer Enrolling: 11/23/2019
Location: University of Colorado Hospital;
Principal Investigator: John Thompson
Protocol #17-0321, No Longer Enrolling: 5/2/2020
Location: University of Colorado Hospital;
Principal Investigator: Jennifer Maitlen
Protocol #20-0292, No Longer Enrolling: 2/11/2020
Location: University of Colorado Hospital;
Participants will be randomized into one of two treatment groups. In one treatment group, participants will receive the quadriceps tendon and patellar bone autograft. The second treatment group will received the all quadriceps tendon autograft. Both graft types are validated and widely used surgical approached in the pediatric and adolescent populations. We will follow participants for up to 5 years following their surgery. Participants' treatment will not differ from the normal standard of care treatment all patients receive, other than being randomized to a particular treatment group and completing questionnaires about pain and physical functioning periodically throughout treatment.
Principal Investigator: STEPHANIE MAYER
Protocol #19-1445, No Longer Enrolling: 2/28/2020
Location: Childrens Hospital Colorado;
Principal Investigator: Chris Lieu
Protocol #20-0365, No Longer Enrolling: 1/8/2021
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04068103
A randomized, double-blind study, placebo-controlled, multi-center, dose-ranging study in hospitalized patients with infected, non-draining pleural effusions. LTI-01 or placebo will be administered through the vein once daily for up to 3 days to facilitate pleural (lung) fluid draining.
Principal Investigator: Ali Musani
Protocol #20-0436, No Longer Enrolling: 9/25/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04234919
To identify genetic and circulating biomarkers of severe bleeding and predictors of brain outcomes in HHT patients. Patients will be evaluated about every 18 months for up to 10 years
Principal Investigator: Cheryl Abbott
Protocol #20-0039, No Longer Enrolling: 6/2/2020
Location: University of Colorado Hospital;
Principal Investigator: Elissa Kolva
Protocol #19-0181, No Longer Enrolling: 6/5/2020
Location: University of Colorado Hospital;
Principal Investigator: Melanie Whittington
Protocol #19-0779, No Longer Enrolling: 6/5/2020
;
Principal Investigator: Amanda Treece
Protocol #19-0922, No Longer Enrolling: 6/5/2020
Location: Childrens Hospital Colorado;
Principal Investigator: Nicholas Cost
Protocol #19-0596, No Longer Enrolling: 6/5/2020
Location: Childrens Hospital Colorado;
Principal Investigator: Daniel LaBarbera
Protocol #19-1407, No Longer Enrolling: 6/5/2020
;
Principal Investigator: MANALI KAMDAR
Protocol #19-1512, No Longer Enrolling: 6/5/2020
Location: University of Colorado Hospital;
Principal Investigator: Elizabeth Ko
Protocol #19-1517, No Longer Enrolling: 6/5/2020
Location: University of Colorado Hospital;
Principal Investigator: Victor Villalobos
Protocol #19-1568, No Longer Enrolling: 6/5/2020
Location: University of Colorado Hospital;
Principal Investigator: Arnold Levinson
Protocol #17-2279, No Longer Enrolling: 6/5/2020
Location: University of Colorado Hospital;
Principal Investigator: Ana Gleisner
Protocol #19-1799, No Longer Enrolling: 6/5/2020
Location: University of Colorado Hospital;
Principal Investigator: Meredith Alston
Protocol #20-0202, No Longer Enrolling: 6/5/2020
Location: Denver Health Medical Center;
Principal Investigator: Donna Wilber
Protocol #20-0232, No Longer Enrolling: 7/14/2020
Location: University of Colorado Hospital;
Principal Investigator: Kristi Engle Folchert
Protocol #20-1325, No Longer Enrolling: 7/16/2020
Location: University of Colorado Hospital;
Principal Investigator: Dianna Quan
Protocol #19-2873, No Longer Enrolling: 7/23/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04136184
This is a clinical trial investigating the effects of the following different radiation and drug pairings of which the patient will be randomly assigned: Radiation therapy and Cisplatin(Standard of Care), Radiation therapy and Cisplatin(Investigational treatment) or Radiation therapy and Docetaxel/ Cetuximab(Investigational treatment)
Principal Investigator: Chelsea Schaefer
Protocol #14-1299, No Longer Enrolling: 2/18/2021
Locations: Lone Tree Medical Center; Memorial Hospital Central; Memorial Hospital North; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT01810913
Principal Investigator: Brianna Blume
Protocol #20-0405, No Longer Enrolling: 8/5/2020
Location: University of Colorado Hospital;
Principal Investigator: Donna Wilber
Protocol #19-1560, No Longer Enrolling: 8/18/2020
Location: University of Colorado Hospital;
This is a mult-center trial where up to 200 pediatric patients will be enrolled. pediatric patients who have a gastrostomy tube placed will be eligible for enrollment and will be randomized to either receive the standard of care tic-tac-toe dressing or the new Button Huggie gastrostomy tube securement device. The patients will be followed at 4, 8, and 12 weeks after placement of the device or dressing to determine satisfaction with the device as well as post-operative outcomes.
Principal Investigator: Jenny Stevens
Protocol #18-1615, No Longer Enrolling: 9/18/2020
Locations: Childrens Hospital Colorado; Childrens Hospital Colorado at Memorial;
Principal Investigator: Austin Larson
Protocol #20-0091, No Longer Enrolling: 10/10/2020
Location: Childrens Hospital Colorado;
More information available at ClinicalTrials.gov: NCT01694953
There will be at least 7 study visits, over 2 years. If symptoms develop visits will be more frequent
Principal Investigator: Deina Barton
Protocol #20-2078, No Longer Enrolling: 10/16/2020
Locations: Anschutz Health and Wellness; Barbara Davis Center; Childrens Hospital Colorado; Renal Research Center;
More information available at ClinicalTrials.gov: NCT04505722
Principal Investigator: Gareth Morgan
Protocol #20-2505, No Longer Enrolling: 2/13/2021
Location: Childrens Hospital Colorado;
Principal Investigator: Sunnie Kim
Protocol #20-1346, No Longer Enrolling: 10/23/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03777657
Principal Investigator: Chris Lieu
Protocol #20-1267, No Longer Enrolling: 12/17/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04479436
Principal Investigator: Jennifer Barker
Protocol #15-150, No Longer Enrolling: 12/1/2020
Location: Childrens Hospital Colorado;
Principal Investigator: Breelyn Wilky
Protocol #20-2809, No Longer Enrolling: 12/11/2020
Location: University of Colorado Hospital;
Principal Investigator: PAULA FISK
Protocol #20-3119, No Longer Enrolling: 1/13/2021
Location: University of Colorado Hospital;
Primary Objective: To evaluate the effectiveness of an 8-week, group-based, Acceptance and Commitment Therapy (ACT) intervention for chronic pain management in cancer survivors who have completed active treatment. Secondary Objective: To evaluate the implementation of an 8-week, group-based, ACT intervention for chronic pain management in cancer survivors who have completed active treatment.
Principal Investigator: Emily Berens
Protocol #18-1102, No Longer Enrolling: 11/12/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03661840
Principal Investigator: Sandra Friedman
Protocol #19-0382, No Longer Enrolling: 4/3/2020
Location: Childrens Hospital Colorado;
This study is a multi-country, multicenter, observational, prospective, longitudinal cohort study which will include patients with a physician diagnosis, or suspected diagnosis, of asthma and/or COPD. Patients will undergo clinical assessments and receive standard medical care as determined by the treating physician. All patients enrolled in the NOVELTY study will be followed up yearly by their treating physician for a total duration of three years. In addition, patients are expected to be followed up remotely once every quarter.
Principal Investigator: Fernando Holguin
Protocol #17-0706, No Longer Enrolling: 12/21/2019
Location: University of Colorado Hospital;
This is a 24 week study to evaluate the safety of using oral treprostinil to treat PH associated with HFpEF
Principal Investigator: Cheryl Abbott
Protocol #17-0163, No Longer Enrolling: 12/3/2019
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03037580
Principal Investigator: Joyce Lee
Protocol #18-2482, No Longer Enrolling: 1/6/2021
Location: University of Colorado Hospital;
Principal Investigator: Alice Gray
Protocol #19-2946, No Longer Enrolling: 12/2/2020
Location: University of Colorado Hospital;
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
Principal Investigator: Cory Dunnick
Protocol #18-1624, No Longer Enrolling: 12/9/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03568318
A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical treatment is medically inadvisable.
Principal Investigator: Elizabeth Wallace
Protocol #19-0144, No Longer Enrolling: 2/18/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03703102
This study is designed to test the effectiveness of the oral drug Apremilast in patients with mild to moderate Plaque Psoriasis. The study lasts ~36 weeks (around 9 months) from start to finish for each participant. There are around 11 scheduled visits throughout the 36 weeks that participants are asked to come to the clinic to see the research team. There are treatment groups and a placebo group in this study. After the first 16 weeks of the study, everyone from the placebo group will be placed into one of the treatment groups. Please direct any further questions or inquries to the Dermatology Clinical Research Team @ 720-848-0556 or diane.ladell@cuanschutz.edu OR daniel.uy@cuanschutz.edu
Principal Investigator: Cory Dunnick
Protocol #18-2578, No Longer Enrolling: 5/2/2020
Location: University of Colorado Hospital;
Principal Investigator: Cory Dunnick
Protocol #18-2798, No Longer Enrolling: 2/13/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03732807
Study B7981032 will investigate PF-06651600 in participants with AA. This is a Phase 3, open-label, multi-center, long-term study designed to evaluate the safety and efficacy of PF-06651600 in adults and adolescents ?12 years of age. The study will have a maximum duration of approximately 26 months. This includes up to a 5-week screening period, a 24-month open-label treatment period, and a 4-week follow-up period (See Schema). Eligible participants will be given the opportunity to enroll from the index studies B7931005 and B7981015, as well as de novo participants (ie, those who have not previously received study intervention in Study B7931005 or B7981015).
Principal Investigator: Cory Dunnick
Protocol #19-2839, No Longer Enrolling: 2/13/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04006457
The study will be a prospective, multi-center, non-randomized, single-arm clinical study to evaluate the effectiveness of SpinalStim.
Principal Investigator: Claire Cofer
Protocol #17-1037, No Longer Enrolling: 8/25/2020
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03176303
Protocol #18-6071, No Longer Enrolling: 10/2/2019
Locations: Memorial Hospital Central; Memorial Hospital North;
More information available at ClinicalTrials.gov: NCT02469857
Principal Investigator: Emily Graves
Protocol #18-0226, No Longer Enrolling: 11/14/2020
Locations: Comprehensive Women's Health Center; Comprehensive Womens Health Center; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT03432416
The primary objective of this study is: To determine the efficacy of maternal immunization with the RSV F vaccine against medically-significant RSV lower respiratory tract infection (LRTI) with EITHER hypoxemia (peripheral oxygen saturation [SpO2] < 95% at sea level or < 92% at altitudes > 1800 meters) OR tachypnea (≥ 70 bpm for infants 0 to 59 days of age or ≥ 60 bpm for infants ≥ 60 days of age) through the first 90 days of life in infants of maternal RSV F vaccinees as compared to placebo recipients. In the event that efficacy is shown through the first 90 days of life, a hierarchical sequence of hypothesis tests will be carried out to examine efficacy at 120, 150, and 180 days of life.
Principal Investigator: Christine Conageski
Protocol #18-1121, No Longer Enrolling: 1/6/2021
Location: University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT02624947
Cepheid is developing a rapid molecular diagnostic test for the detection of Group B Strep (GBS), a bacterial infection associated with serious illness in newborns born to women who are have a GBS infection. This study will collect specimens from pregnant women for the development of a prototype assay (laboratory test).
Protocol #18-2283, No Longer Enrolling: 10/17/2019
Location: University of Colorado Hospital;
Principal Investigator: Ahmed (Rony) Marwan
Protocol #15-1141, No Longer Enrolling: 9/12/2020
Location: Childrens Hospital Colorado;
If you join the study, you will participate in two study sessions, which can be completed either in-person (at Anschutz Medical Campus, in Aurora, CO) or remotely - over the internet, over the course of 2 months. The first part of the study is the screening session. During this session, the research staff will conduct an interview with you and complete questionnaires about your medical and mental health history, and your mood. The second and last part of the study is the test session. During this session, you will complete surveys about your mood, and you will rate 160 digital images. Forty of those images will be pleasant, 40 will be unpleasant, 40 will be neutral, and 40 will be erotic. You will rate these images on scales of how pleasant/unpleasant and of how arousing/non-arousing you find these images.To investigate ratings of digital images across the female menstrual cycle
Principal Investigator: Andrew Novick
Protocol #19-2872, No Longer Enrolling: 1/20/2021
Locations: Department Specific Free Standing Clinic; University of Colorado, Boulder;
Principal Investigator: Jenna Buehler
Protocol #19-2780, No Longer Enrolling: 10/20/2020
Locations: Greeley Campus; Harmony Campus; Medical Center of the Rockies; Memorial Hospital Central; Memorial Hospital North; Poudre Valley Hospital; University of Colorado Hospital;
More information available at ClinicalTrials.gov: NCT04034927